研究活動情報

• 2024年06月 日本内分泌学会, 研究奨励賞


• 2023年05月 United Japanese researchers Around the world (UJA)論文賞 特別賞


• 2021年03月 The Endocrine Society’s 101st Annual Meeting and Expo (ENDO2021), Outstanding Abstract Award


• 2020年11月 The University of Michigan Postdoctoral Association, Conference Award


• 2020年03月 The Office of Graduate & Postdoctoral Studies, University of Michigan Medical School, Travel Award


• 2019年03月 The Endocrine Society, Early Career Forum Travel Award


• 2019年03月 The Endocrine Society’s 101st Annual Meeting and Expo (ENDO2019), Outstanding Abstract Award


• 2018年01月 神戸大学 糖尿病内分泌内科, Jump-up Award


• 2017年04月 日本内分泌学会, 若手研究奨励賞 (YIA)


• 2015年03月 14th International Pituitary Congress, Travel grant


• 2014年10月 7th International Congress of the GRS and IGF Society, Travel grant


• 2013年01月 日本内分泌学会, 第22回臨床内分泌代謝Update, トラベルグラント


• 2013年01月 日本内分泌学会, 第22回臨床内分泌代謝Update, 優秀ポスター賞

• Glucocorticoid Resistance Syndrome as a Hidden Cause of Nonneoplastic Hypercortisolism

  Naoki Yamamoto, Nozomi Kido, Kenji Sugawara, Hironori Bando, Masaaki Yamamoto, Shin Urai, Yasutaka Tsujimoto, Yuka Ohmachi, Yuma Motomura, Yuka Oi-Yo, Yuriko Sasaki, Masaki Suzuki, Michiko Takahashi, Genzo Iguchi, Wataru Ogawa, Hidenori Fukuoka

  2025年05月, Journal of the Endocrine Society

  研究論文（学術雑誌）


• Intracystic catecholamine variations in cystic pheochromocytoma

  Tomoko Fujii, Hironori Bando, Masaaki Yamamoto, Maki Kanzawa, Keitaro Kanie, Shin Urai, Yasutaka Tsujimoto, Fumikazu Sawabe, Keiko Fukazawa, Asa Hanayama, Tomoko Yamada, Kei Yoshino, Hidenori Fukuoka, Wataru Ogawa

  2025年04月, Journal of Endocrinological Investigation

  研究論文（学術雑誌）


• Body mass index and metabolic complications in individuals with treatment-naïve acromegaly

  Naoki Yamamoto, Shin Urai, Masaaki Yamamoto, Masaki Suzuki, Yasutaka Tsujimoto, Hironori Bando, Yuma Motomura, Yuka Ohmachi, Yuriko Sasaki, Yuka Oi-Yo, Michiko Takahashi, Genzo Iguchi, Hidenori Fukuoka, Wataru Ogawa

  2025年, Endocrine Journal

  研究論文（学術雑誌）


• Utility of gel filtration chromatography in evaluating successful resection of ectopic adrenocorticotropic hormone-producing tumor: a case report and literature review

  Mei Nakatsuji, Hironori Bando, Masaaki Yamamoto, Maki Kanzawa, Takefumi Doi, Yasutaka Tsujimoto, Kei Yoshino, Hidenori Fukuoka, Itsuko Sato, Yoshihiko Yano, Yugo Tanaka, Wataru Ogawa

  2025年, Endocrine Journal

  研究論文（学術雑誌）


• Hypopituitarism: genetic, developmental, and acquired etiologies with a focus on the emerging concept of autoimmune hypophysitis

  Hironori Bando, Shin Urai, Keitaro Kanie, Masaaki Yamamoto

  2025年, Endocrine Journal

  研究論文（学術雑誌）


• Sodium-glucose cotransporter-2 inhibitor-associated thrombocytopenia

  Hironori Bando, Yushi Hirota, Wataru Ogawa

  2024年11月, Hormones

  研究論文（学術雑誌）


• 急激な症状の顕在化と共に下垂体卒中を来したCushing病の一例

  高橋 直人, 樋口 雄一, 辻本 泰貴, 浦井 伸, 坂東 弘教, 山田 倫子, 山本 雅昭, 神澤 真紀, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年10月, 日本内分泌学会雑誌, 100(2) (2), 590 - 590, 日本語


• 腫瘍別にMIBG集積性が異なった両側褐色細胞腫の1例

  乾 妃那, 坂東 弘教, 山本 雅昭, 神澤 真紀, 本村 悠馬, 福岡 秀規, 齋藤 剛, 小川 渉

  (一社)日本内分泌学会, 2024年10月, 日本内分泌学会雑誌, 100(2) (2), 623 - 623, 日本語


• 腫瘍別にMIBG集積性が異なった両側褐色細胞腫の1例

  乾 妃那, 坂東 弘教, 山本 雅昭, 神澤 真紀, 本村 悠馬, 福岡 秀規, 齋藤 剛, 小川 渉

  (一社)日本内分泌学会, 2024年10月, 日本内分泌学会雑誌, 100(2) (2), 623 - 623, 日本語


• 急激な症状の顕在化と共に下垂体卒中を来したCushing病の一例

  高橋 直人, 樋口 雄一, 辻本 泰貴, 浦井 伸, 坂東 弘教, 山田 倫子, 山本 雅昭, 神澤 真紀, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年10月, 日本内分泌学会雑誌, 100(2) (2), 590 - 590, 日本語


• Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan.

  Yuka Oi-Yo, Masaaki Yamamoto, Shin Urai, Hironori Bando, Yuka Ohmachi, Yuma Motomura, Masaki Kobatake, Yasutaka Tsujimoto, Yuriko Sasaki, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi, Hidenori Fukuoka

  PURPOSE: To elucidate the long-term efficacy and safety of growth hormone replacement therapy (GHRT) in Japanese patients with adult growth hormone deficiency (AGHD). METHODS: We conducted a retrospective study. A total of 110 patients with AGHD receiving GHRT were enrolled. Clinical and laboratory data were collected annually from the beginning of the study. Statistical analysis was performed using a linear mixed-effects model. RESULTS: Of all patients, 46.4% were males, 70.9% had adult-onset GHD, and follow-up was up to 196 months, with a median of 68 months. The insulin-like growth factor-1 standard deviation score increased after the start of GHRT and remained constant for more than 11 years. Seventeen patients were followed up for more than 11 years. The body mass index increased. Waist circumference decreased in the short term but increased in the long term. The diastolic blood pressure decreased 1-5 years after the start of GHRT, and the systolic blood pressure increased 11 years after GHRT. Moreover, a long-term decrease in low-density lipoprotein cholesterol, an increase in high-density lipoprotein cholesterol, and a decrease in aspartate aminotransferase and alanine aminotransferase levels were observed. The glycosylated hemoglobin level increased after 3 years. The bone mineral density in the lumbar spine and total hip increased significantly 3 years after the start of GHRT. Finally, the number of adverse events was eight. CONCLUSION: We demonstrated the metabolic effectiveness and safety of GHRT in Japanese patients with AGHD over a long follow-up period of 16 years.

  2024年09月, Pituitary, 英語, 国際誌

  研究論文（学術雑誌）


• Understanding negative feedback: Changes in high-molecular-weight adrenocorticotropic hormone in adrenocorticotropic hormone-independent Cushing's syndrome.

  Yuto Ichinose, Mei Nakatsuji, Hironori Bando, Masaaki Yamamoto, Maki Kanzawa, Kei Yoshino, Hidenori Fukuoka, Wataru Ogawa

  Cushing's syndrome is characterized by chronic glucocorticoid oversecretion and diverse clinical manifestations. Distinguishing between adrenocorticotropic hormone (ACTH)-independent and ACTH-dependent forms is crucial for determining treatment options. Plasma ACTH levels aid in the differential diagnosis, with undetectable or low levels suggesting ACTH-independent hypercortisolemia. ACTH is derived from pro-opiomelanocortin, and its processing involves prohormone convertase 1/3. High-molecular-weight ACTH is generally found in ACTH-producing pituitary tumors and ectopic ACTH syndrome. The mechanism of negative feedback and the process of high-molecular-weight ACTH alternation during ACTH-independent Cushing's syndrome remain unclear. A 40-year-old woman with hypertension and multiple fractures developed symptoms suggestive of Cushing's syndrome. Computed tomography revealed a left adrenocortical tumor along with atrophy of the right adrenal gland. ACTH levels were undetectable at the previous clinic, indicating ACTH-independent Cushing's syndrome. However, subsequent measurements at our hospital revealed non-suppressed ACTH (18.1 pg/mL), prompting further investigation. Gel exclusion chromatography confirmed the presence of high-molecular-weight ACTH. Metyrapone treatment decreased the cortisol levels. In this situation, in which ACTH levels should be elevated, a decrease in high-molecular-weight ACTH levels was observed. Histological findings revealed cortisol-producing adenoma without ACTH expression. This case highlights the importance of assay differences in evaluating ACTH concentrations and introduces a novel finding of circulating high-molecular-weight ACTH. The observed decline in high-molecular-weight ACTH levels suggests a potential time lag in the negative feedback within the hypothalamic-pituitary-adrenal axis exhibited by glucocorticoids. This temporal aspect of the regulation of ACTH-related molecules warrants further exploration to enhance our understanding of the hypothalamic-pituitary-adrenal axis feedback mechanism.

  2024年08月, Journal of neuroendocrinology, e13438, 英語, 国際誌

  研究論文（学術雑誌）


• Acquired isolated ACTH deficiency co-occurrence with breast cancer irrespective of paraneoplastic syndrome: coincidence or inevitability.

  Shin Urai, Hironori Bando, Mei Nakatsuji, Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  SUMMARY: A 52-year-old female patient with breast cancer presented with a history of fatigue and malaise 1 year prior. She was diagnosed with isolated adrenocorticotropic hormone (ACTH) deficiency (IAD) on endocrinological examination. Her pituitary gland showed normal morphology. Paraneoplastic IAD associated with breast cancer was suspected; however, immunofluorescence staining revealed no ectopic ACTH or proopiomelanocortin expression in the tumor tissue. Subsequently, the patient was diagnosed with idiopathic acquired IAD concurrent with breast cancer, ruling out paraneoplastic syndrome. Although malignancy should be considered a potential cause of IAD, not all patients with concurrent IAD and malignancy necessarily develop paraneoplastic syndrome. LEARNING POINTS: Several adrenal insufficiency symptoms are similar to the nonspecific symptoms associated with malignancies, and therefore, the diagnosis of IAD remains challenging, especially in patients with cancer. When we encounter a case of IAD accompanied by a malignant tumor, it is important to suspect that paraneoplastic IAD, a novel clinical condition as secondary hypophysitis, may be the etiologic agent. Although malignant tumours should be considered a potential cause of IAD, not all patients with concurrent IAD and malignancy necessarily develop paraneoplastic autoimmune hypophysitis.

  2024年07月, Endocrinology, diabetes & metabolism case reports, 2024(3) (3), 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Diagnostic dilemma in Cushing's syndrome: discrepancy between patient-reported and physician-assessed manifestations.

  Yuma Motomura, Shin Urai, Hironori Bando, Masaaki Yamamoto, Masaki Suzuki, Naoki Yamamoto, Genzo Iguchi, Wataru Ogawa, Hidenori Fukuoka

  PURPOSE: Early diagnosis and immediate treatment of Cushing's syndrome (CS) are critical for a better prognosis but remain a challenge. However, few comprehensive reports have focused on this issue or investigated whether patient-reported manifestations are consistent with physician-assessed symptoms of CS. This study aimed to clarify the differences in patient-reported and physician-assessed manifestations of signs and symptoms of CS that prevent early diagnosis. METHODS: This single-center retrospective study included 52 patients with CS (16 with Cushing's disease and 36 with adrenal CS). Upon clinical diagnosis, medical records were used to independently review the patient-reported and physician-assessed manifestations of typical (such as purple striae and proximal myopathy) and nonspecific features (such as hirsutism and hypertension). The correlations and differences between the patient-reported and physician-assessed manifestations were then analyzed. RESULTS: We observed a positive correlation between the total number of manifestations of nonspecific features reported by patients and those assessed by physicians, but not for typical features. Moreover, manifestations reported by the patients were less frequent than those assessed by physicians for typical features, leading to discrepancies between the two groups. In contrast, there were no differences in most nonspecific features between the patient-reported and physician-assessed manifestations. Notably, the concordance between patient-reported and physician-assessed manifestations of typical features was not associated with urinary free cortisol levels. CONCLUSION: Regardless of disease severity, patients often do not complain of the typical features of CS that are crucial for formulating a diagnosis.

  2024年06月, Endocrine, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Acquired thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone deficiencies with circulating anti-glycoprotein hormones alpha chain-positive cell antibodies.

  Hironori Bando, Masaaki Yamamoto, Genzo Iguchi, Wataru Ogawa

  BACKGROUND: A patient with systemic lupus erythematosus (SLE) suffered from acquired thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) deficiencies. MRI findings revealed a slight atrophy of the pituitary gland. Further, the serum concentration of the covalent alpha subunit (glycoprotein hormones alpha chain [CGA]) in TSH-, LH-, and FSH-positive cells was below the detectable range. Because SLE is an autoimmune disorder, autoimmunity against the pituitary gland was suspected as the cause of pituitary deficiency. METHODS AND RESULTS: Immunofluorescence analysis showed that the patient's immunoglobulin G recognized CGA-positive cells in the pituitary gland; therefore, autoimmunity against CGA-positive cells may have caused TSH, LH, and FSH deficiencies in this patient. Moreover, cell-specific autoimmunity impairs pituitary hormone levels. Further research is required to clarify whether acquired TSH, LH, and FSH deficiencies are common in patients with SLE or other autoimmune diseases. CONCLUSION: Our findings highlight a unique case of acquired TSH, LH, and FSH deficiencies caused by circulating anti-CGA-positive cell antibodies, introducing a novel clinical concept of acquired hypopituitarism.

  2024年06月, Endocrine, 英語, 国際誌

  研究論文（学術雑誌）


• Effects of soy or whey protein on weight reduction in patients with obesity: An exploratory, three-arm, placebo-controlled, double-blind, randomized clinical trial

  Michiko Takahashi, Takumi Imai, Tomoko Yamada, Naokazu Muramae, Kai Yoshimura, Yuji Mitomo, Hironori Bando, Kenji Sugawara, Shun-Ichiro Asahara, Yushi Hirota, Yoshikazu Tamori, Yutaka Takahashi, Wataru Ogawa

  Elsevier BV, 2024年06月, Clinical Nutrition Open Science, 55, 223 - 233

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Dailyからweekly GH製剤への切り替え後よりインスリン量の週内調節が必要となった1型糖尿病合併汎下垂体機能低下症の1例

  樋口 雄一, 福岡 秀規, 芳野 啓, 坂東 弘教, 山本 雅昭, 廣田 勇士, 小川 渉

  (一社)日本内分泌学会, 2024年05月, 日本内分泌学会雑誌, 100(1) (1), 332 - 332, 日本語


• メチラポン,カベルゴリン併用からオシロドロスタットへの切り替えを行った94歳Cushing病の一例

  津本 一秀, 山本 雅昭, 坂東 弘教, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年05月, 日本内分泌学会雑誌, 100(1) (1), 370 - 370, 日本語


• The early-stage clinical course of anti-pituitary-specific transcription factor-1 hypophysitis diagnosed post-immune checkpoint inhibitor treatment: A case with review of literature

  Urai, S., Tomofuji, S., Bando, H., Kanzawa, M., Yamamoto, M., Fukuoka, H., Tsuda, M., Iguchi, G., Ogawa, W.

  2024年04月, Journal of Neuroendocrinology, 36(6) (6)

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Thyroid dysfunction due to trace element deficiency—not only selenium but also zinc

  Nagano, K., Motomura, Y., Bando, H., Yamamoto, M., Kanie, K., Yoshino, K., Hirota, Y., Yamada, T., Takahashi, M., Fukuoka, H., Ogawa, W.

  2024年04月, Hormones

  研究論文（学術雑誌）


• 抗PD-1抗体阻害薬投与後に発症した膵臓MRI所見と血清CPRの経時的な変化を発症早期より確認し得た劇症1型様の糖尿病の一例

  友藤 清爾, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年04月, 糖尿病, 67(Suppl.1) (Suppl.1), S - 176, 日本語


• 他科入院中患者に対する糖尿病内科医の併診業務の診療実態とその経時的推移

  芳野 啓, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年04月, 糖尿病, 67(Suppl.1) (Suppl.1), S - 190, 日本語


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年04月, 日本内分泌学会雑誌, 99(5) (5), 1430 - 1430, 日本語


• COVID-19関連の神経内分泌病態 COVID-19ワクチン接種後に著明な低Na血症と意識障害を呈した一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年04月, 日本内分泌学会雑誌, 99(5) (5), 1393 - 1393, 日本語


• 偽性Cushing症候群を契機に同定に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年04月, 日本内分泌学会雑誌, 99(5) (5), 1423 - 1423, 日本語


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2024年04月, 日本内分泌学会雑誌, 99(5) (5), 1430 - 1430, 日本語


• Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph Tumors

  Kanzawa, M., Shichi, H., Kanie, K., Yamamoto, M., Yamamoto, N., Tsujimoto, Y., Bando, H., Iguchi, G., Kitano, S., Inoshita, N., Yamada, S., Ogawa, W., Itoh, T., Fukuoka, H.

  2024年02月, Endocrinology (United States), 165(4) (4)

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• ハイブリッドクローズドループ(HCL)療法下でフルマラソンを完走した1型糖尿病の2例

  乾 妃那, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 84 - 84, 日本語


• 多職種連携のもとで実施した減量・代謝改善手術4例の経験

  芳野 啓, 廣田 勇士, 裏川 直樹, 山木 愛久, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 85 - 85, 日本語


• 緩徐な経過を辿った免疫関連副作用(irAE)による1型様の糖尿病の1例

  齋藤 修一郎, 芳野 啓, 小畠 正樹, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 89 - 89, 日本語


• 複数の膵島関連自己抗体が陽性だがprobable判定であった緩徐進行1型糖尿病の1例

  湯川 恒弘, 深澤 圭似子, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 102 - 102, 日本語


• Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis

  Hironori Bando, Masaaki Yamamoto, Shin Urai, Yuma Motomura, Yuriko Sasaki, Yuka Ohmachi, Masaki Kobatake, Yasutaka Tsujimoto, Yuka Oi-Yo, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  2024年02月, Journal for ImmunoTherapy of Cancer, 12(2) (2)

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.

  Yuka Ohmachi, Masaaki Yamamoto, Yuiko Inaba, Shohei Makino, Shin Urai, Risa Matsumoto, Hironori Bando, Keitaro Kanie, Yasutaka Tsujimoto, Yuma Motomura, Yuriko Sasaki, Yuka Oi-Yo, Naoki Yamamoto, Masaki Suzuki, Michiko Takahashi, Genzo Iguchi, Maki Kanzawa, Junya Furukawa, Katsumi Shigemura, Satoshi Mizobuchi, Wataru Ogawa, Hidenori Fukuoka

  PURPOSE: Preoperative medical management is critical to prevent intraoperative cardiovascular complications in patients with pheochromocytomas and paragangliomas (PPGLs). Initial treatment involves α-adrenergic receptor blockers. However, while the routine use of metyrosine alongside these blockers is not strongly recommended due to a lack of evidence supporting its efficacy and associated safety concerns, there are previous studies on combination therapy with phenoxybenzamine and metyrosine. There are few reports on combination therapy with the selective α1-adrenergic receptor blocker doxazosin. Therefore, we investigated this combination treatment, which theoretically can affect perioperative outcomes in patients with PPGLs. To our knowledge, this is the first such study. METHODS: This retrospective single-center observational study involved 51 patients who underwent surgical resection of PPGLs at Kobe University Hospital between 2014 and 2022. All patients received doxazosin at maximum doses. Fourteen patients received concomitant metyrosine, while 37 received doxazosin alone. Their perioperative outcomes were compared. RESULTS: No severe event, such as acute coronary syndrome, was observed in either group. Intraoperatively, the doxazosin + metyrosine group exhibited a lower median minimum systolic blood pressure (56 [54-60] vs. 68 [59-74] mmHg, P = 0.03) and required lower median remifentanil (P = 0.04) and diltiazem (P = 0.02) doses than the doxazosin-alone group. CONCLUSION: The combination of metyrosine and doxazosin as a preoperative treatment for PPGLs affects intraoperative circulatory hemodynamics, such as a reduced occurrence of blood pressure elevation during surgery. Further research is necessary to identify patients who will benefit most from this combination treatment.

  2024年01月, Endocrine, 英語, 国際誌

  研究論文（学術雑誌）


• Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: A new aspect of paraneoplastic autoimmune condition

  Urai, S., Iguchi, G., Kanie, K., Bando, H., Yamamoto, M., Oi, Y., Kashitani, Y., Iida, K., Kanzawa, M., Fukuoka, H., Takahashi, M., Shintani, Y., Ogawa, W., Takahashi, Y.

  2024年01月, European Journal of Endocrinology, 190(1) (1)

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Metyrapone single administration, as a possible predictive tool of its dosage and timing in Cushing's syndrome.

  Yasutaka Tsujimoto, Naoki Yamamoto, Hironori Bando, Masaaki Yamamoto, Yuka Ohmachi, Yuma Motomura, Yuka Oi-Yo, Yuriko Sasaki, Masaki Suzuki, Shin Urai, Michiko Takahashi, Genzo Iguchi, Wataru Ogawa, Hidenori Fukuoka

  Metyrapone is commonly used in the initial management of Cushing's syndrome to reduce hypercortisolemia, but its optimal dosage and timing can vary significantly between patients. Currently, there are limited guidelines on adjustment methods for its administration to individual needs. This study aimed to evaluate responsiveness of each patient to metyrapone and identify the patient characteristics associated with the indices of cortisol responsiveness following a low-dose metyrapone. This single-center retrospective observational study included 15 treatment-naïve patients, 7 of whom had Cushing's disease and 8 had adrenal Cushing's syndrome. Serum cortisol levels were measured hourly from the time of administration of 250 mg of metyrapone up to four hours afterward. Parameters analyzed included the nadir of serum cortisol levels (Fnadir), the difference between basal and nadir serum cortisol levels (ΔF), the time to nadir, and the characteristics of the patients. As a result, cortisol suppression curves showed significant variability among patients, particularly in the time to nadir. While the median time to nadir was 2 hours, 20% of patients required 4 hours or more, and these responses were not associated with patient characteristics. Fnadir was positively correlated with early-morning serum cortisol levels, serum cortisol levels after low-dose dexamethasone suppression test (LDDST), and urinary free cortisol (UFC) levels, whereas ΔF was positively correlated with late-night serum cortisol levels, serum cortisol levels after LDDST, and UFC levels. In conclusion, the duration of response to metyrapone appeared unpredictable in patients with Cushing's syndrome and did not correlate with patient characteristics at baseline. Tracking the effect of metyrapone following a single low-dose administration may explain this variability and provide insights for optimizing individual dosing regimens. Further studies are required to validate these findings and guide more personalized treatment adjustments.

  2024年, Frontiers in endocrinology, 15, 1511155 - 1511155, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.

  Yuma Motomura, Shin Urai, Yushi Hirota, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Wataru Ogawa

  We present a case of type 1 diabetes mellitus (T1DM) that developed in a 53-year-old man after long-term treatment with nivolumab. The patient underwent total gastrectomy for gastric cancer at 40 years of age, and he was started on nivolumab at age 48 years for treatment of a recurrent lesion that proved resistant to standard chemotherapy. Nivolumab treatment resulted in complete response, but, after the 136th infusion of the drug at age 53 years, the patient was hospitalized for sudden onset of diabetic ketoacidosis. He was diagnosed with immune checkpoint inhibitor-induced T1DM (ICI-DM), which developed 1988 days (284 weeks) after initiation of nivolumab. HLA typing revealed disease susceptibility alleles for both fulminant T1DM and ICI-DM. With the increased survival after the ICI treatment, delayed-onset irAEs after long-term use of ICI have been reported; however, delayed-onset ICI-DM remains to be elucidated. This case provides important insight into ICI-DM that develops after prolonged ICI administration, and it suggests that patients should be monitored for ICI-DM regardless of the duration of ICI therapy.

  2024年01月, Diabetology international, 15(1) (1), 130 - 134, 英語, 国内誌

  神戸大学リポジトリ（Kernel）へのリンク


• Anaplastic Thyroid Carcinoma With Air Spaces

  Masaki Suzuki, Hironori Bando

  2023年12月, JCEM Case Reports

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Newer parameters of the octreotide test in patients with acromegaly.

  Shin Urai, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Hidenori Fukuoka, Michiko Takahashi, Genzo Iguchi, Yutaka Takahashi, Wataru Ogawa

  PURPOSE: Predicting the therapeutic effects of first-generation somatostatin receptor ligands (fg-SRLs) is important when assessing or planning effective treatment strategies in patients with acromegaly. The oft-used maximum growth hormone (GH) suppression rate parameter of the octreotide test has a suboptimal predictive value. Therefore, this study explored newer parameters of the octreotide test for predicting the therapeutic effect of long-acting fg-SRLs. METHODS: In this single-center retrospective study, the octreotide test parameters and the therapeutic effects of fg-SRL at 3 months were investigated in 45 consecutive treatment-naïve patients with acromegaly between April 2008 and March 2023. Additionally, the relationship between the octreotide test parameters and the therapeutic effects of fg-SRLs was investigated. Tumor shrinkage was evaluated based on changes in the longitudinal diameter of the macroadenomas. The area GH suppression rate-time under the curve (AUC) and the time to nadir GH level were calculated and compared with the maximum GH suppression rate. RESULTS: The AUC estimated reductions in serum insulin-like growth factor I, and tumor shrinkage. The time to nadir GH level predicted tumor shrinkage more robustly than the maximum GH suppression rate in patients with macroadenoma. CONCLUSION: The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.

  2023年11月, Pituitary, 英語, 国際誌

  研究論文（学術雑誌）


• Composite paraganglioma-ganglioneuroma with atypical catecholamine profile and phenylethanolamine N-methyltransferase expression: a case report and literature review.

  Yuriko Sasaki, Maki Kanzawa, Masaaki Yamamoto, Keitaro Kanie, Hironori Bando, Kei Yoshino, Yushi Hirota, Katsumi Shigemura, Masato Fujisawa, Wataru Ogawa, Hidenori Fukuoka

  Pheochromocytomas and paragangliomas (PPGLs) are rare tumors that secrete catecholamines and arise from the adrenal medulla or extra-adrenal sympathetic ganglia. These tumors secrete adrenaline and noradrenaline, but paragangliomas usually produce only noradrenaline because of the lack of phenylethanolamine N-methyltransferase (PNMT) expression. Composite paragangliomas, which are complex tumors consisting of multiple types of neuroblastic cells, are extremely rare. We present the case of a 46-year-old woman with an atypical catecholamine profile who was preoperatively diagnosed with pheochromocytoma. However, postoperative pathology revealed that the patient had an extra-adrenal paraganglioma accompanied by a ganglioneuroma, which led to the diagnosis of a composite tumor. Interestingly, PNMT is expressed in both paragangliomas and ganglioneuromas. In addition, we reviewed reported composite paragangliomas and compared their clinical features with those of composite pheochromocytomas. We also discuss various aspects of the etiology of composite paragangliomas and the mechanism by which PNMT is expressed in tumors.

  2023年11月, Endocrine journal, 英語, 国内誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• 74歳で診断に至ったSCS合併Sheehan症候群の一例

  草壁 明日香, 坂東 弘教, 山本 雅昭, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 587 - 587, 日本語


• 染色体、薬剤、環境の複合的な寄与が考えられた骨粗鬆症の一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 608 - 608, 日本語


• ラトケ嚢胞における染色マーカーの有用性と臨床像の関連

  佐々木 百合子, 坂東 弘教, 神澤 真紀, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 井口 元三, 山本 雅昭, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, 日本語


• 偽性Cushing症候群から発見に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, 日本語


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 590 - 590, 日本語


• クッシング症候群におけるメチラポン単回投与への反応性の検討

  辻本 泰貴, 山本 雅昭, 坂東 弘教, 山本 直希, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 浦井 伸, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 622 - 622, 日本語


• A new insight into GH regulation and its disturbance from nutrition and autoimmune perspectives.

  Masaaki Yamamoto, Hironori Bando

  GH activates GH receptors, which activates IGF-1 in the liver through a cascade of processes. The GH/IGF-1 axis plays an important role in the regulation of metabolism. Insufficient GH secretion results in short stature in childhood, while adult GH deficiency (AGHD) is observed in adulthood. The early diagnosis of AGHD is important for early initiation of GH replacement therapy. This review described the regulatory mechanisms of GH signaling based on nutritional status and a novel disease concept pathogenesis that causes AGHD. GH-dependent IGF-1 production in the liver is regulated by a complex interplay between nutritional status, hormones, and growth factors. GH resistance is an adaptive response that enhances survival during starvation and malnutrition. Sirtuin 1 (SIRT1) negatively regulates GH-induced IGF-I production in the liver by directly inhibiting STAT5 activation, which causes GH resistance under starvation and malnutrition. The presence of autoantibodies is strongly associated with the disruption of immune tolerance in pituitary cells. Pituitary-specific transcription factors (PIT-1) are essential for the development, differentiation, and maintenance of GH, PRL, and TSH producing cells. However, the underlying mechanism that causes immune intolerance to PIT-1 remain unclear. The GH-IGF-1 system plays a pivotal role in growth, and the involvement of SIRT1 in this regulatory mechanism presents an intriguing perspective on the interplay between nutrient metabolism and lifespan. The discovery of the anti-PIT-1 pituitary antibody, a novel disease concept associated with AGHD, has provided valuable insights, which serves as a significant milestone towards unraveling the complete pathogenesis of the disease.

  2023年08月, Endocrine journal, 英語, 国内誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Flame-like Calcifications in Werner Syndrome

  Yasutaka Tsujimoto, Hironori Bando

  2023年07月, JCEM Case Reports

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Instability of harmonized thyroid-stimulating hormone immunoassays in clinical practice.

  Kenichi Uto, Hironori Bando, Hidenori Fukuoka, Masaaki Yamamoto, Ayako Ogasahara, Shoko Ono, Chinami Oyabu, Itsuko Sato, Takamitsu Imanishi, Jun Saegusa, Wataru Ogawa, Yoshihiko Yano

  OBJECTIVE: Thyroid-stimulating hormone (TSH) harmonization is effective in minimizing differences between the results of immunoassays in healthy subjects. However, the effectiveness of TSH harmonization in clinical practice has not been investigated. The aim of this study was to evaluate the instability of TSH harmonization in clinical practice. METHODS: We compared the reactivities of four harmonized TSH immunoassays using combined difference plots of 431 patients. We selected patients with statistically significant deviations in TSH levels and analyzed their thyroid hormone levels and clinical characteristics. RESULTS: The combined difference plots showed that one harmonized TSH immunoassay exhibited markedly different reactivity even after TSH harmonization compared with the other three immunoassays. Among 109 patients with mild-to-moderate elevation of TSH levels, we selected 15 patients with statistically significant deviations in TSH levels according to the difference plots of three harmonized TSH immunoassays, excluding one immunoassay that showed different reactivity. The thyroid hormone levels of three patients were misclassified as hypothyroidism or normal due to deviating TSH levels. In terms of clinical characteristics, these patients were in poor nutritional status and general condition, possibly due to their severe illness (e.g., advanced metastatic cancer). CONCLUSION: We have confirmed that TSH harmonization in clinical practice is relatively stable. However, some patients showed deviating TSH levels in the harmonized TSH immunoassays, indicating the need for caution, particularly in poorly nourished patients. This finding suggests the presence of factors that contribute to the instability of TSH harmonization in such cases. Further investigation is warranted to validate these results.

  2023年06月, Clinical endocrinology, 英語, 国際誌

  研究論文（学術雑誌）


• 免疫チェックポイント阻害薬が惹起した腫瘍随伴性ACTH単独欠損症

  渡邊 美季, 浦井 伸, 坂東 弘教, 本村 悠馬, 神澤 真紀, 立原 素子, 山本 雅昭, 福岡 秀規, 井口 元三, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 295 - 295, 日本語


• 抗PIT-1下垂体炎新規2例を加えた9症例の臨床的特徴

  浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 大井 佑夏, 樫谷 悠也, 飯田 啓二, 神澤 真紀, 福岡 秀規, 井口 元三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 311 - 311, 日本語


• ラトケ嚢胞の病理学的診断におけるKRT8の有用性

  佐々木 百合子, 坂東 弘教, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 大町 侑香, 辻本 泰貴, 大井 佑夏, 鈴木 正暉, 山本 直希, 井口 元三, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 332 - 332, 日本語


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 51 - 54, 日本語


• Gonadotroph tumorとsomatotroph tumorのcollisionと考えられた一例

  神澤 真紀, 辻本 泰貴, 山本 雅昭, 蟹江 慶太郎, 坂東 弘教, 中井 友昭, 篠山 隆司, 井下 尚子, 福岡 秀規, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, 2023年03月, 日本内分泌学会雑誌, 98(5) (5), 1636 - 1636, 日本語


• Survey of glucocorticoid dose escalation in patients with adrenal insufficiency during the peri-COVID-19 vaccination period.

  Hironori Bando, Masaaki Yamamoto, Michiko Takahashi, Keitaro Kanie, Yuriko Sasaki, Yuka Oi, Seiji Tomofuji, Kaori Hozumi, Seiji Nishikage, Shin Urai, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Hidenori Fukuoka, Wataru Ogawa

  There is uncertainty regarding the need for COVID-19 peri-vaccination glucocorticoid coverage in patients with adrenal insufficiency. In this survey conducted in a single tertiary medical institution, 167 consecutive outpatients taking physiological glucocorticoids because of adrenal insufficiency were included. The patients declared if they developed an adrenal crisis after vaccination, and the amount and duration of an increase in their glucocorticoid dosage, if any. None of the patients without preventive glucocorticoid increase suffered an adrenal crisis after COVID-19 vaccination. Only 8.3% (14 cases) and 27.5% (46 cases) of the patients needed to escalate the dose of glucocorticoids when systemic symptoms appeared after the first and second injections, respectively. Glucocorticoids were increased in patients <60 years of age more than in patients ≥60 years of age at the time of both the first (p = 0.026) and second injections (p = 0.005). Sex and the causes of adrenal insufficiency were not associated with the frequency of the patients who needed glucocorticoid dose escalation. In the cases with increased glucocorticoids, the median dosage for escalation was 10 mg (hydrocortisone equivalent). In conclusion, even without prophylactic glucocorticoid administration, adrenal crisis did not occur during the peri-COVID-19 vaccination period. The dose escalation of steroid was more frequent in younger patients following the second vaccination. Careful monitoring of adverse effects and the appropriate management of glucocorticoids when necessary are essential following COVID-19 vaccinations.

  2023年01月, Endocrine journal, 70(1) (1), 89 - 95, 英語, 国内誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Heterozygous variants in SIX3 and POU1F1 cause pituitary hormone deficiency in mouse and man.

  Hironori Bando, Michelle L Brinkmeier, Frederic Castinetti, Qing Fang, Mi-Sun Lee, Alexandru Saveanu, Frédérique Albarel, Clémentine Dupuis, Thierry Brue, Sally A Camper

  Congenital hypopituitarism is a genetically heterogeneous condition that is part of a spectrum disorder that can include holoprosencephaly. Heterozygous mutations in SIX3 cause variable holoprosencephaly in humans and mice. We identified two children with neonatal hypopituitarism and thin pituitary stalk who were doubly heterozygous for rare, likely deleterious variants in the transcription factors SIX3 and POU1F1. We used genetically engineered mice to understand the disease pathophysiology. Pou1f1 loss of function heterozygotes are unaffected; Six3 heterozygotes have pituitary gland dysmorphology and incompletely ossified palate; and the Six3+/-; Pou1f1+/dw double; heterozygote mice have a pronounced phenotype, including pituitary growth through the palate. The interaction of Pou1f1 and Six3 in mice supports the possibility of digenic pituitary disease in children. Disruption of Six3 expression in the oral ectoderm completely ablated anterior pituitary development, and deletion of Six3 in the neural ectoderm blocked development of the pituitary stalk and both anterior and posterior pituitary lobes. Six3 is required in both oral and neural ectodermal tissues for activation of signaling pathways and transcription factors necessary for pituitary cell fate. These studies clarify the mechanism of SIX3 action in pituitary development and provide support for a digenic basis for hypopituitarism.

  2023年01月, Human molecular genetics, 32(3) (3), 367 - 385, 英語, 国際誌

  研究論文（学術雑誌）


• Preoperative Serum Cortisol Level Is Predictive of Weight Loss After Laparoscopic Sleeve Gastrectomy in Men with Severe Obesity but Not Women.

  Hironori Bando, Hiroshi Miura, Seiichi Kitahama, Shinsuke Nakajima, Tetsuya Takahashi, Toshihiko Mihara, Teppei Momono, Maki Kimura-Koyanagi, Kazuhiko Sakaguchi, Tomoichiro Mukai, Wataru Ogawa, Yoshikazu Tamori

  BACKGROUND: Bariatric surgery is an effective treatment for severe obesity and its associated medical problems. Preoperative factors that predict postoperative weight loss remain to be fully characterized, however. METHODS: Anthropometric and laboratory data were collected retrospectively for severely obese patients who underwent laparoscopic sleeve gastrectomy (LSG) between April 2016 and July 2019 at our hospital. Preoperative factors that predicted weight loss at 1 year after LSG were investigated. RESULTS: A total of 122 subjects (45 men and 77 women) underwent LSG. The mean ± SD age and body mass index at surgery were 44.4 ± 10.4 years and 40.7 ± 6.7 kg/m2. The percent total weight loss (%TWL) was 27.0 ± 8.6 among all subjects, 26.4 ± 8.0 among men, and 27.4 ± 8.9 among women, with no significant difference between the sexes. The %TWL showed a significant inverse correlation with serum cortisol level in men and with age and the visceral/subcutaneous fat area ratio in women. Multivariable regression analysis revealed the presence of type 2 diabetes and the serum cortisol concentration to be negatively associated with %TWL among all subjects and men, respectively. Receiver operating characteristic curve analysis identified an optimal cutoff of 10 µg/dL for prediction of a %TWL of ≥ 25 in men by serum cortisol level. CONCLUSIONS: Serum cortisol concentration was identified as a predictor for postoperative weight loss in men. Our results may thus help inform the decision to perform LSG or more effective surgical procedures in men with severe obesity.

  2023年01月, Obesity surgery, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.

  Yasunori Fujita, Fumika Kamitani, Masaaki Yamamoto, Hidenori Fukuoka, Yushi Hirota, Nobuharu Nishiyama, Naho Goda, Yuko Okada, Yuiko Inaba, Hiroki Nakajima, Yukako Kurematsu, Keitaro Kanie, Hiroki Shichi, Shin Urai, Masaki Suzuki, Naoki Yamamoto, Hironori Bando, Genzo Iguchi, Hirotaka Suto, Yohei Funakoshi, Naomi Kiyota, Yutaka Takahashi, Wataru Ogawa

  CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.

  2023年01月, Journal of the Endocrine Society, 7(3) (3), bvad002, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.

  Shin Urai, Miki Watanabe, Hironori Bando, Yuma Motomura, Masaaki Yamamoto, Motoko Tachihara, Maki Kanzawa, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa

  INTRODUCTION: A recently discovered facet of paraneoplastic adrenocorticotropic hormone (ACTH) deficiency exists in two forms: a paraneoplastic spontaneous isolated ACTH deficiency (IAD) and an immune checkpoint inhibitor (ICI)-related hypophysitis. Autoantibodies against corticotrophs, such as circulating anti-proopiomelanocortin (POMC) antibodies are considered disease markers. However, the number of identified cases was limited, implying that the characteristics of these autoantibodies are not fully understood. METHODS: We investigate circulating autoimmune autoantibodies in detail through a novel case of IAD that developed as a paraneoplastic autoimmune ACTH deficiency. RESULTS: The patient developed IAD after 25 weeks of ICI therapy for metastasis of large-cell neuroendocrine carcinoma at 69 years of age. Ectopic ACTH expression and infiltration of CD3+, CD4+, CD8+, and CD20+ lymphocytes were observed in the tumor tissues and circulating anti-POMC antibodies were detected specifically in the patient's serum. Moreover, detailed analyses of immunofluorescence staining using patient serum revealed that the recognition site of the autoantibody was ACTH25-39, which had not been identified in previous cases of paraneoplastic autoimmune ACTH deficiency. CONCLUSION: This case involved a combination of paraneoplastic spontaneously acquired IAD and ICI-related hypophysitis occupying the middle ground. Moreover, our study reveals new aspects of anti-POMC antibodies in patients with paraneoplastic ACTH deficiency. This report expands our understanding of the immunological landscape and provides new insights for the identification of antibodies associated with paraneoplastic autoimmune ACTH deficiency.

  2023年, Frontiers in immunology, 14, 1284301 - 1284301, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Successful diagnosis and treatment of pheochromocytoma during severe coronavirus disease 2019 (COVID-19): a case report.

  Yasutaka Tsujimoto, Masaaki Yamamoto, Seiji Nishikage, Keitaro Kanie, Maki Kanzawa, Hironori Bando, Kei Yoshino, Yushi Hirota, Hidenori Fukuoka, Wataru Ogawa

  Pheochromocytoma is a rare but life-threatening condition due to catecholamine release induced by drug treatments such as β-blockers or glucocorticoids. We present a case of hypertensive crisis due to pheochromocytoma, induced after the initiation of dexamethasone and landiolol during intensive care for severe coronavirus disease 2019 (COVID-19). Based on a detailed medical history review, the patient was previously diagnosed with primary aldosteronism by confirmatory tests, moreover, an abdominal computed tomography scan identified an adrenal tumor 2 years before current admission. We tentatively diagnosed the patient with pheochromocytoma and initiated α-blockers without conducting a catecholamine report, leading to stable hemodynamics. We present a successfully managed case of pheochromocytoma concomitant with COVID-19, which has become a global crisis.

  2022年11月, Endocrine journal, 英語, 国内誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• High Cortisol Concentration Without Cushingoid Appearance.

  Hironori Bando, Keitaro Kanie, Masaaki Yamamoto, Hidenori Fukuoka

  2022年11月, The American journal of medicine, 英語, 国際誌


• ヒトiPS細胞を用いた下垂体疾患研究

  松本 隆作, 蟹江 慶太郎, 坂東 弘教, 山本 拓也, 高橋 裕

  (有)科学評論社, 2022年09月, 糖尿病・内分泌代謝科, 55(3) (3), 333 - 340, 日本語


• Author Correction: Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics.

  Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, Wataru Ogawa

  2022年08月, Scientific reports, 12(1) (1), 13238 - 13238, 英語, 国際誌


• 輸血によりゴナドトロピン単独欠損症を呈した再生不良性貧血の一例

  山本 直希, 浦井 伸, 山本 雅昭, 坂東 弘教, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年08月, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 81 - 83, 日本語


• 輸血によりゴナドトロピン単独欠損症を呈した再生不良性貧血の一例

  山本 直希, 浦井 伸, 山本 雅昭, 坂東 弘教, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年08月, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 81 - 83, 日本語


• Bilateral adrenal uptake of 123I MIBG scintigraphy with mild catecholamine elevation, the diagnostic dilemma, and its characteristics.

  Yuiko Inaba, Masaaki Yamamoto, Shin Urai, Masaki Suzuki, Seiji Nishikage, Maki Kanzawa, Yayoi Aoyama, Tomonori Kanda, Katsumi Shigemura, Hironori Bando, Genzo Iguchi, Yasuhiro Nakamura, Masato Fujisawa, Akihisa Imagawa, Hidenori Fukuoka, Wataru Ogawa

  Cases in which bilateral adrenal 123I-Metaiodobenzylguanidine (123I-MIBG) scintigraphy accumulation is sometimes shown, with mildly elevated catecholamine (CA) or metanephrine (MN) levels (within 3 times the upper reference limit) are diagnostic dilemmas. We experienced 3 cases of adrenal incidentalomas with this dilemma in the differential diagnosis. The clinical diagnosis was subclinical Cushing's syndrome in 2 cases, and primary aldosteronism in 1. Despite suspected CA excess in clinical symptoms and imaging findings, the pathological findings of all these tumors were revealed to be cytochrome P450 family 11 subfamily B member 1 (CYP11B1) positive adrenocortical adenomas. Interestingly, adrenal medullary hyperplasia (AMH) was detected in the adrenal parenchyma of all those backgrounds. To clarify the clinical features of such cases, a cross-sectional study was conducted at the Kobe University Hospital from 2014 to 2020. One-hundred sixty-four patients who had undergone 123I-MIBG scintigraphy were recruited. Among them, 10 patients (6.1%) met the above criteria, including the presented 3 cases. Plasma adrenaline, noradrenaline, urinary metanephrine, and normetanephrine had values of 0.05 ± 0.05 ng/mL, 0.63 ± 0.32 ng/mL, 0.22 ± 0.05 mg/day, and 0.35 ± 0.16 mg/day, respectively. Nine cases were complicated with hypertension, and symptoms related to CA excess were observed. Half of them (5 cases) including presented 3 cases had unilateral adrenal tumors. These suggest that in cases of bilateral adrenal uptake on 123I-MIBG, AMH needs to be considered. Adrenocortical adenomas may be associated with AMH and further larger investigation is needed for this pathology.

  2022年06月, Scientific reports, 12(1) (1), 9276 - 9276, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.

  Hiroki Shichi, Hidenori Fukuoka, Maki Kanzawa, Masaaki Yamamoto, Naoki Yamamoto, Masaki Suzuki, Shin Urai, Ryusaku Matsumoto, Keitaro Kanie, Yasunori Fujita, Hironori Bando, Genzo Iguchi, Naoko Inoshita, Shozo Yamada, Yutaka Takahashi, Wataru Ogawa

  PURPOSE: To clarify the characteristics of Cushing's disease (CD) patients who respond to the desmopressin (DDAVP) test and its underlying mechanisms. METHODS: Forty-seven patients with CD who underwent DDAVP testing were included. Patients were divided into two groups: DDAVP test (+) (adrenocorticotropic hormone [ACTH] levels increased by ≥ 1.5-fold during the DDAVP test) and DDAVP test (-) (ACTH levels increased by < 1.5-fold). AVP receptor expression levels in these tumors were quantified using quantitative RT-PCR and immunohistochemistry. AVP receptor promoter activity was analyzed using a dual-luciferase reporter assay system. RESULTS: Females (96.9%) and USP8 mutants (85.7%) were more prevalent in the DDAVP test (+) than in the DDAVP test (-). Indeed, the ACTH and cortisol responsiveness to DDAVP was greater in USP8 mutation positive tumors than that in USP8 wild type tumors (3.0-fold vs. 1.3-fold, 1.6-fold vs. 1.1-fold, respectively). Responsiveness to DDAVP was correlated with the expression levels of AVPR1B, but not with those of AVPR2. Comparably, Avpr1b promoter activity was enhanced by the overexpression of mutant USP8 compared to the wild type. CONCLUSIONS: We found that the responsiveness of ACTH to DDAVP in CD was greater in tumors with USP8 mutations. The present data suggest that USP8 mutations upregulate the AVPR1B promoter activity. Additionally, we showed that the DDAVP test can predict the presence of USP8 mutations.

  2022年04月, Pituitary, 25(3) (3), 496 - 507, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• 末梢血FKBP5遺伝子発現はACTH非依存性に血中コルチゾールと関連する

  鈴木 正暉, 山本 雅昭, 佐々木 百合子, 大井 佑夏, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 高橋 路子, 坂東 弘教, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 315 - 315, 日本語


• 内科における先端巨大症管理 単一施設成績

  辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 千原 和夫, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, 日本語


• 先端巨大症患者におけるBMIで層別化した肥満関連疾患の有病率

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, 日本語


• 当院における成人成長ホルモン分泌不全症患者のGH治療による耐糖能変化に寄与する因子の検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 345 - 345, 日本語


• 1型糖尿病と自己免疫性甲状腺疾患との関連についての検討

  藤井 研己, 芳野 啓, 山本 あかね, 上田 真莉子, 松岡 敦子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 197, 日本語


• Free StyleリブレLink使用者の背景および導入前後におけるスキャン回数、HbA1cの変化の検討

  花山 亜沙, 上田 真莉子, 松岡 敦子, 山本 あかね, 蟹江 慶太郎, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 208, 日本語


• 若年で糖尿病を発症した小児がん経験者の1例

  佐々木 百合子, 坂東 弘教, 藤井 研己, 西影 星二, 山本 雅昭, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 231, 日本語


• 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデル樹立と進展防止のための創薬への応用

  蟹江 慶太郎, 伊藤 剛, 井口 元三, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 小川 渉, 金子 新, 高橋 裕

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 272 - 272, 日本語


• 末梢血FKBP5遺伝子発現はACTH非依存性に血中コルチゾールと関連する

  鈴木 正暉, 山本 雅昭, 佐々木 百合子, 大井 佑夏, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 高橋 路子, 坂東 弘教, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 315 - 315, 日本語


• 内科における先端巨大症管理 単一施設成績

  辻本 泰貴, 蟹江 慶太郎, 山本 雅昭, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 千原 和夫, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, 日本語


• 先端巨大症患者におけるBMIで層別化した肥満関連疾患の有病率

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 331 - 331, 日本語


• 当院における成人成長ホルモン分泌不全症患者のGH治療による耐糖能変化に寄与する因子の検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 345 - 345, 日本語


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 160, 日本語


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 161, 日本語


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, 日本語


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 神澤 真紀, 山本 雅昭, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年03月, 日本内分泌学会雑誌, 97(5) (5), 1622 - 1622, 日本語


• Case report: Late middle-aged features of FAM111A variant, Kenny-Caffey syndrome type 2-suggestive symptoms during a long follow-up.

  Yuka Ohmachi, Shin Urai, Hironori Bando, Jun Yokoi, Masaaki Yamamoto, Keitaro Kanie, Yuma Motomura, Yasutaka Tsujimoto, Yuriko Sasaki, Yuka Oi, Naoki Yamamoto, Masaki Suzuki, Hiroki Shichi, Genzo Iguchi, Natsumi Uehara, Hidenori Fukuoka, Wataru Ogawa

  Kenny-Caffey syndrome type 2 (KCS2) is an extremely rare skeletal disorder involving hypoparathyroidism and short stature. It has an autosomal dominant pattern of inheritance and is caused by variants in the FAM111 trypsin-like peptidase A (FAM111A) gene. This disease is often difficult to diagnose due to a wide range of more common diseases manifesting hypoparathyroidism and short stature. Herein, we present the case of a 56-year-old female patient with idiopathic hypoparathyroidism and a short stature. The patient was treated for these conditions during childhood. Upon re-evaluating the etiology of KCS2, we suspected that the patient had the disorder because of clinical manifestations, such as cortical thickening and medullary stenosis of the bones, and lack of intellectual abnormalities. Genetic testing identified a heterozygous missense variant in the FAM111A gene (p.R569H). Interestingly, the patient also had bilateral sensorineural hearing loss and vestibular dysfunction, which have been rarely described in previous reports of pediatric cases. In KCS2, inner ear dysfunction due to Eustachian tube dysfunction may progress in middle age or later. However, this disease is now being reported in younger patients. Nevertheless, our case may be instructive of how such cases emerge chronically after middle age. Herein, we also provide a literature review of KCS2.

  2022年, Frontiers in endocrinology, 13, 1073173 - 1073173, 英語, 国際誌

  神戸大学リポジトリ（Kernel）へのリンク


• Novel genes and variants associated with congenital pituitary hormone deficiency in the era of next-generation sequencing.

  Hironori Bando, Shin Urai, Keitaro Kanie, Yuriko Sasaki, Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Sally A Camper

  Combined pituitary hormone deficiency (CPHD) is not a rare disorder, with a frequency of approximately 1 case per 4,000 live births. However, in most cases, a genetic diagnosis is not available. Furthermore, the diagnosis is challenging because no clear correlation exists between the pituitary hormones affected and the gene(s) responsible for the disorder. Next-generation sequencing (NGS) has recently been widely used to identify novel genes that cause (or putatively cause) CPHD. This review outlines causative genes for CPHD that have been newly reported in recent years. Moreover, novel variants of known CPHD-related genes (POU1F1 and GH1 genes) that contribute to CPHD through unique mechanisms are also discussed in this review. From a clinical perspective, variants in some of the recently identified causative genes result in extra-pituitary phenotypes. Clinical research on the related symptoms and basic research on pituitary formation may help in inferring the causative gene(s) of CPHD. Future NGS analysis of a large number of CPHD cases may reveal new genes related to pituitary development. Clarifying the causative genes of CPHD may help to understand the process of pituitary development. We hope that future innovations will lead to the identification of genes responsible for CPHD and pituitary development.

  2022年, Frontiers in endocrinology, 13, 1008306 - 1008306, 英語, 国際誌

  [査読有り]

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Paraneoplastic autoimmune hypophysitis: An emerging concept.

  Hironori Bando, Keitaro Kanie, Yutaka Takahashi

  Pituitary autoimmunity is one of the principal causes of hypopituitarism. Additionally, hypophysitis is one of the immune-related adverse events associated with immunotherapy. Recent case-oriented research has revealed a novel type of autoimmune hypophysitis, anti-PIT-1 hypophysitis, related to isolated adrenocorticotropic hormone (ACTH) deficiency and immune checkpoint inhibitor-related hypophysitis, as a form of paraneoplastic syndrome. Under these conditions, the ectopic expression of pituitary antigens present in tumors evokes a breakdown of immune tolerance, resulting in the production of autoantibodies and autoreactive cytotoxic T cells that specifically harm pituitary cells. Consequently, an innovative clinical entity of paraneoplastic autoimmune hypophysitis has been purported. This novel concept and its underlying mechanisms provide clues for understanding the pathogenesis of autoimmune pituitary diseases and can be applied to other autoimmune diseases. This review discusses the etiology of paraneoplastic autoimmune hypophysitis and its future.

  2021年11月, Best practice & research. Clinical endocrinology & metabolism, 101601 - 101601, 英語, 国際誌

  [査読有り][招待有り]

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• 発症36年後に抗ラブフィリン3A抗体陽性を示した尿崩症の1例

  西影 星二, 山本 雅昭, 稲葉 惟子, 坂東 弘教, 芳野 啓, 廣田 勇士, 椙村 益久, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 505 - 505, 日本語


• COVID-19治療中の高血圧クリーゼから診断した褐色細胞腫の一例

  辻本 泰貴, 西影 星二, 山本 雅昭, 西坂 まり華, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 坂東 弘教, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 528 - 528, 日本語


• ICIとTKI使用後に原発性副腎不全を生じた腎癌の2例

  西坂 まり華, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 533 - 533, 日本語


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 山本 雅昭, 神澤 真紀, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 539 - 539, 日本語


• 胸腺腫術後に重症筋無力症を発症した抗PIT-1下垂体炎の1例

  大井 佑夏, 山本 雅昭, 浦井 伸, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 487 - 487, 日本語


• USP8変異はV1b受容体発現、DDAVP試験反応性亢進と関連する

  志智 大城, 福岡 秀規, 神澤 真紀, 山本 直希, 鈴木 正暉, 浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 山田 正三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 501 - 501, 日本語


• High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency.

  Peter Gergics, Cathy Smith, Hironori Bando, Alexander A L Jorge, Denise Rockstroh-Lippold, Sebastian A Vishnopolska, Frederic Castinetti, Mariam Maksutova, Luciani Renata Silveira Carvalho, Julia Hoppmann, Julián Martínez Mayer, Frédérique Albarel, Debora Braslavsky, Ana Keselman, Ignacio Bergadá, Marcelo A Martí, Alexandru Saveanu, Anne Barlier, Rami Abou Jamra, Michael H Guo, Andrew Dauber, Marilena Nakaguma, Berenice B Mendonca, Sajini N Jayakody, A Bilge Ozel, Qing Fang, Qianyi Ma, Jun Z Li, Thierry Brue, María Ines Pérez Millán, Ivo J P Arnhold, Roland Pfaeffle, Jacob O Kitzman, Sally A Camper

  Pituitary hormone deficiency occurs in ∼1:4,000 live births. Approximately 3% of the cases are due to mutations in the alpha isoform of POU1F1, a pituitary-specific transcriptional activator. We found four separate heterozygous missense variants in unrelated individuals with hypopituitarism that were predicted to affect a minor isoform, POU1F1 beta, which can act as a transcriptional repressor. These variants retain repressor activity, but they shift splicing to favor the expression of the beta isoform, resulting in dominant-negative loss of function. Using a high-throughput splicing reporter assay, we tested 1,070 single-nucleotide variants in POU1F1. We identified 96 splice-disruptive variants, including 14 synonymous variants. In separate cohorts, we found two additional synonymous variants nominated by this screen that co-segregate with hypopituitarism. This study underlines the importance of evaluating the impact of variants on splicing and provides a catalog for interpretation of variants of unknown significance in POU1F1.

  2021年07月, American journal of human genetics, 英語, 国際誌

  [査読有り]

  研究論文（学術雑誌）


• Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.

  Keitaro Kanie, Genzo Iguchi, Hironori Bando, Shin Urai, Hiroki Shichi, Yasunori Fujita, Ryusaku Matsumoto, Kentaro Suda, Masaaki Yamamoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as hypophysitis, have been associated with the use of ICIs. Most underlying mechanisms of ICI-related hypophysitis remain unclear, especially for programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors. We hypothesized that ICI-related hypophysitis is associated with paraneoplastic syndrome caused by ectopic expression of pituitary-specific antigens. METHODS: Twenty consecutive patients with ICI-related hypophysitis between 2017 and 2019 at Kobe University Hospital were retrospectively analyzed. Circulating anti-pituitary antibodies were detected using immunofluorescence staining and immunoblotting. Ectopic expression of pituitary autoantigens in tumor specimens was also examined. RESULTS: Eighteen patients were treated with PD-1/PD-L1 inhibitors, and two were treated with a combination of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and PD-1 inhibitors. All patients showed adrenocorticotropic hormone (ACTH) deficiency and additionally, three showed thyroid-stimulating hormone (TSH) deficiency, and one showed gonadotropin-releasing hormone (GnRH) deficiency. Among these patients, three exhibited anti-pituitary antibodies, two with anti-corticotroph antibody and one with anti-somatotroph antibody. Interestingly, the anti-corticotroph antibody recognized proopiomelanocortin (POMC) and those two patients exhibited ectopic ACTH expression in the tumor, while the patients without anti-corticotroph antibody did not. CONCLUSIONS: We demonstrated 10% of PD-1/PD-L1 inhibitors-related hypophysitis were associated with the autoimmunity against corticotrophs and maybe caused as a form of paraneoplastic syndrome, in which ectopic expression of ACTH in the tumor was observed. It is also suggested that the pathophysiology is heterogenous in ICI-related hypophysitis.

  2021年05月, Cancer immunology, immunotherapy : CII, 70(12) (12), 3669 - 3677, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• SIX3 Variant Causes Pituitary Stalk Interruption Syndrome and Combined Pituitary Hormone Deficiency

  Bando H, Brinkmeier M, Gergics P, Fang Q, Mortensen A, Ozel A, Ma Q, Li J, Reynaud R, Castinetti F, Brue T, Camper S

  2021年05月, Journal of the Endocrine Society

  研究論文（学術雑誌）


• The phenotypic spectrum associated with OTX2 mutations in humans.

  Louise Cheryl Gregory, Peter Gergics, Marilena Nakaguma, Hironori Bando, Giuseppa Patti, Mark James McCabe, Qing Fang, Qianyi Ma, Asye Bilge Ozel, Jun Z Li, Michele Moreira Poina, Alexander Augusto de Lima Jorge, Anna F Figueredo Benedetti, Antonio Lerario, Ivo Jp Arnhold, Berenice Bilharinho Mendonca, Mohamad Maghnie, Sally Camper, Luciani Rs Carvalho, Mehul Tulsidas Dattani

  OBJECTIVE: The transcription factor OTX2 is implicated in ocular, craniofacial, and pituitary development. DESIGN: We aimed to establish the contribution of OTX2 mutations in congenital hypopituitarism patients with/without eye abnormalities, study functional consequences, and establish OTX2 in the human brain, with a view to investigating the mechanism of action. METHODS: We screened patients from the UK (n=103), international centers (n=24), and Brazil (n=282); 145 were within the septo-optic dysplasia spectrum, and 264 had no eye phenotype. Transactivation ability of OTX2 variants was analysed in murine hypothalamic GT1-7 neurons. In situ hybridization was performed on human embryonic brain sections. Genetically engineered mice were generated with a series of C-terminal OTX2 variants. RESULTS: Two chromosomal deletions and six haploinsufficient mutations were identified in individuals with eye abnormalities; an affected relative of one patient harboured the same mutation without an ocular phenotype. OTX2 truncations led to significant transactivation reduction. A missense variant was identified in another patient without eye abnormalities, however studies revealed it was most likely not causative. In the mouse, truncations proximal to aa219 caused anophthalmia, while distal truncations and the missense variant were tolerated. During human embryogenesis, OTX2 was expressed in the posterior pituitary, retina, ear, thalamus, choroid plexus, and partially in the hypothalamus, but not in the anterior pituitary. CONCLUSIONS: OTX2 mutations are rarely associated with hypopituitarism in isolation without eye abnormalities, and may be variably penetrant, even within the same pedigree. Our data suggest that the endocrine phenotypes in patients with OTX2 mutations are of hypothalamic origin.

  2021年05月, European journal of endocrinology, 英語, 国際誌

  研究論文（学術雑誌）


• Pituitary tumors and immortalized cell lines generated by cre-inducible expression of SV40 T antigen.

  Alexandre Z Daly, Amanda H Mortensen, Hironori Bando, Sally A Camper

  Targeted oncogenesis is the process of driving tumor formation by engineering transgenic mice that express an oncogene under the control of a cell-type specific promoter. Such tumors can be adapted to cell culture, providing immortalized cell lines. To make it feasible to follow the process of tumorigenesis and increase the opportunity for generating cell lines, we developed a mouse strain that expresses SV40 T antigens in response to cre-recombinase. Using CRISPR/Cas9 we inserted a cassette with coding sequences for SV40 T antigens and an internal ribosome entry site with green fluorescent protein cassette (IRES-GFP) into the Rosa26 locus, downstream from a stop sequence flanked by loxP sites: Rosa26LSL-SV40-GFP. These mice were mated with previously established Prop1-cre and Tshb-cre transgenic lines. Both the Rosa26LSL-SV40-GFP/+; Prop1-cre and Rosa26LSL-SV40-GFP/+; Tshb-cre mice developed fully penetrant dwarfism and large tumors by 4 weeks. Tumors from both of these mouse lines were adapted to growth in cell culture. We have established a progenitor-like cell line (PIT-P1) that expresses Sox2 and Pitx1, and a thyrotrope-like cell line (PIT-T1) that expresses Pou1f1 and Cga. These studies demonstrate the utility of the novel, Rosa26LSL-SV40-GFP mouse line for reliable targeted oncogenesis and development of unique cell lines.

  The Endocrine Society, 2021年04月, Endocrinology, 英語, 国際誌

  研究論文（学術雑誌）


• A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling.

  Kentaro Suda, Hidenori Fukuoka, Genzo Iguchi, Keitaro Kanie, Yasunori Fujita, Yukiko Odake, Ryusaku Matsumoto, Hironori Bando, Hiroki Ito, Michiko Takahashi, Kazuo Chihara, Hiroshi Nagai, Satoshi Narumi, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahashi

  CONTEXT: Luscan-Lumish syndrome (LLS) is characterized by postnatal overgrowth, obesity, Chiari I malformation, seizures, and intellectual disability. SET domain-containing protein 2 (SETD2) is a histone methyltransferase, where mutations in the gene are associated with the development of LLS. However, mechanisms underlying LLS remain unclear. CASE DESCRIPTION: A 20-year-old man was referred to our hospital because of tall stature. His body height was 188.2 cm (+3.18 SD) and he showed obesity with a body mass index of 28.4 kg/m2. He exhibited acral overgrowth, jaw malocclusion, and prognathism, but no history of seizures, intellectual disability, or speech delay. Serum growth hormone (GH), insulin-like growth factor 1 (IGF-1), and nadir GH levels after administration of 75 g oral glucose were within normal range. Pituitary magnetic resonance imaging showed no pituitary adenoma, but Chiari I malformation. Whole exome sequencing analysis of the proband revealed a de novo heterozygous germline mutation in SETD2 (c.236T>A, p.L79H). Skin fibroblasts derived from the patient grew faster than those from his father and the control subject. In addition, these cells showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH. CONCLUSION: This is a mild case of LLS with a novel mutation in SETD2 without neurological symptoms. LLS should be differentiated in a patient with gigantism without pituitary tumors. Although further investigation is necessary, this is the first study to suggest the involvement of aberrant GH signaling in the development of LLS.

  2021年03月, The Journal of clinical endocrinology and metabolism, 106(3) (3), 718 - 723, 英語, 国際誌

  研究論文（学術雑誌）


• Two Cases of anti-PIT-1 Hypophysitis Exhibited as a Form of Paraneoplastic Syndrome not Associated With Thymoma.

  Keitaro Kanie, Genzo Iguchi, Megumi Inuzuka, Kentaro Sakaki, Hironori Bando, Shin Urai, Hiroki Shichi, Yasunori Fujita, Ryusaku Matsumoto, Kentaro Suda, Masaaki Yamamoto, Hidenori Fukuoka, Takao Taniguchi, Wataru Ogawa, Yutaka Takahashi

  Anti-pituitary-specific transcription factor 1 (PIT-1) hypophysitis (anti-PIT-1 antibody syndrome) is a thymoma-associated autoimmune disease characterized by acquired growth hormone (GH), prolactin (PRL), and thyrotropin (TSH) deficiencies due to autoimmunity against PIT-1. Ectopic expression of PIT-1 in the thymoma plays a causal role in development of the disease. Here, we report 2 cases of anti-PIT-1 hypophysitis exhibiting as a form of paraneoplastic syndrome with conditions other than thymoma. A 79-year-old woman (case 1) and an 86-year-old man (case 2) were referred with a suspicion of anti-PIT-1 hypophysitis because of acquired GH, PRL, and TSH deficiencies. Case 1 was complicated by diffuse large B-cell lymphoma (DLBCL) of the bladder and case 2 was diagnosed with malignancy with multiple metastases of unknown origin. Because circulating anti-PIT-1 antibody was detected, both patients were diagnosed with anti-PIT-1 hypophysitis. Circulating PIT-1-reactive T cells were detected in case 1 via enzyme-linked immunospot (ELISPOT) assay. Interestingly, the PIT-1 protein was ectopically expressed in the DLBCL cells of case 1, whereas DLBCL tissues derived from patients without anti-PIT-1 hypophysitis were negative for PIT-1. In case 2, the materials were not available because of best supportive care was under way. These data show that anti-PIT-1 hypophysitis is associated not only with thymoma but also with other malignancies. Additionally, the ectopic expression of PIT-1 in the DLBCL tissues and presence of PIT-1-reactive T cells suggested that the underlying mechanisms were similar to those observed in thymoma. Thus, anti-PIT-1 hypophysitis is defined as a form of paraneoplastic syndrome.

  2021年03月, Journal of the Endocrine Society, 5(3) (3), bvaa194, 英語, 国際誌


• 抗PIT-1下垂体炎

  山本雅昭, 蟹江慶太郎, 坂東弘教

  2021年, 月刊糖尿病・内分泌代謝科, 53(2) (2)


• Clinical Heterogeneity of Acquired Idiopathic Isolated Adrenocorticotropic Hormone Deficiency.

  Yasunori Fujita, Hironori Bando, Genzo Iguchi, Keiji Iida, Hitoshi Nishizawa, Keitaro Kanie, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  Objective: Heterogeneous clinical characteristics are observed in acquired isolated adrenocorticotropic hormone (ACTH) deficiency (IAD); however, its classification remains to be established because of its largely unknown pathophysiology. In IAD, anti-pituitary antibodies have been detected in some patients, although their significance remains unclear. Therefore, this study aimed to classify patients with IAD and to clarify the significance of anti-pituitary antibodies. Design and Methods: We analyzed 46 consecutive patients with IAD. Serum anti-pituitary antibodies were analyzed via immunofluorescence staining using a mouse pituitary tissue. Principal component and cluster analyses were performed to classify IAD patients based on clinical characteristics and autoantibodies. Results: Immunofluorescence analysis using the sera revealed that 58% of patients showed anti-corticotroph antibodies and 6% of patients showed anti-follicular stellate cell (FSC) antibodies. Principal component analysis demonstrated that three parameters could explain 70% of the patients. Hierarchical cluster analysis showed three clusters: Groups A and B comprised patients who were positive for anti-corticotroph antibodies, and plasma ACTH levels were extremely low. Groups A and B comprised middle-aged or elderly men and middle-aged women, respectively. Group C comprised patients who were positive for the anti-FSC antibody and elderly men; plasma ACTH levels were relatively high. Conclusions: Patients with IAD were classified into three groups based on clinical characteristics and autoantibodies. The presence of anti-corticotroph antibody suggested severe injury to corticotrophs. This new classification clearly demonstrated the heterogeneity in the pathogenesis of IAD.

  Frontiers Media SA, 2021年, Frontiers in endocrinology, 12, 578802 - 578802, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports.

  Tomoko Yamada, Hidenori Fukuoka, Yusei Hosokawa, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yuko Okada, Yushi Hirota, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Plasma renin activity (PRA) is generally increased in patients with pheochromocytoma (PCC) due to low circulating plasma volume and activation of β-1 adrenergic receptor signaling. However, there has been no study on the aldosterone renin ratio (ARR) in patients with PCC. To elucidate the issue, this study aimed to determine the PRA, plasma aldosterone concentration (PAC), and ARR in patients with PCC and compare them with those in patients with subclinical Cushing's syndrome (SCS) and non-functioning adrenal adenoma (NFA). METHODS: In this retrospective single-center, cross-sectional study, 67 consecutive patients with adrenal tumors (PCC (n = 18), SCS (n = 18), and NFA (n = 31)) diagnosed at Kobe University Hospital between 2008 and 2014 were enrolled. RESULTS: PRA was significantly higher in patients with PCC than in those with SCS and NFA (2.1 (1.3 ~ 2.8) vs. 0.7 (0.5 ~ 1.8) and 0.9 (0.6 ~ 1.4) ng/mL/h; p = 0.018 and p = 0.025). Although PACs were comparable among the three groups, ARR was significantly lower in patients with PCC than in those with SCS and NFA (70.5 (45.5 ~ 79.5) vs. 156.0 (92.9 ~ 194.5) and 114.9 (90.1 ~ 153.4); p = 0.001 and p < 0.001). Receiver operating characteristic curve analysis demonstrated that, in differentiating PCC from NFA, PRA > 1.55 ng/mL/h showed a sensitivity of 70.0% and specificity of 80.6%. Interestingly, ARR < 95.4 showed a sensitivity of 83.3% and specificity of 86.7%, which were higher than those in PRA. CONCLUSIONS: ARR decreased in patients with PCC, which was a more sensitive marker than PRA. Further study is necessary to understand the usefulness of this convenient marker in the detection of PCC. TRIAL REGISTRATION: This study was not registered because of the retrospective analysis.

  2020年09月, BMC endocrine disorders, 20(1) (1), 140 - 140, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Rathke's cleft-like cysts arise from Isl1 deletion in murine pituitary progenitors.

  Michelle L Brinkmeier, Hironori Bando, Adriana C Camarano, Shingo Fujio, Koji Yoshimoto, Flávio Sj de Souza, Sally A Camper

  The transcription factor ISL1 is expressed in pituitary gland stem cells and the thyrotrope and gonadotrope lineages. Pituitary-specific Isl1 deletion causes hypopituitarism with increased stem cell apoptosis, reduced differentiation of thyrotropes and gonadotropes, and reduced body size. Conditional Isl1 deletion causes development of multiple Rathke's cleft-like cysts, with 100% penetrance. Foxa1 and Foxj1 are abnormally expressed in the pituitary gland and associated with a ciliogenic gene-expression program in the cysts. We confirmed expression of FOXA1, FOXJ1, and stem cell markers in human Rathke's cleft cyst tissue, but not craniopharyngiomas, which suggests these transcription factors are useful, pathological markers for diagnosis of Rathke's cleft cysts. These studies support a model whereby expression of ISL1 in pituitary progenitors drives differentiation into thyrotropes and gonadotropes and without it, activation of FOXA1 and FOXJ1 permits development of an oral epithelial cell fate with mucinous cysts. This pituitary-specific Isl1 mouse knockout sheds light on the etiology of Rathke's cleft cysts and the role of ISL1 in normal pituitary development.

  2020年08月, The Journal of clinical investigation, 130(8) (8), 4501 - 4515, 英語, 国際誌

  研究論文（学術雑誌）


• Otx2b mutant zebrafish have pituitary, eye and mandible defects that model mammalian disease.

  Hironori Bando, Peter Gergics, Brenda L Bohnsack, Kevin P Toolan, Catherine E Richter, Jordan A Shavit, Sally A Camper

  Combined pituitary hormone deficiency (CPHD) is a genetically heterogeneous disorder caused by mutations in over 30 genes. The loss-of-function mutations in many of these genes, including orthodenticle homeobox 2 (OTX2), can present with a broad range of clinical symptoms, which provides a challenge for predicting phenotype from genotype. Another challenge in human genetics is functional evaluation of rare genetic variants that are predicted to be deleterious. Zebrafish are an excellent vertebrate model for evaluating gene function and disease pathogenesis, especially because large numbers of progeny can be obtained, overcoming the challenge of individual variation. To clarify the utility of zebrafish for the analysis of CPHD-related genes, we analyzed the effect of OTX2 loss of function in zebrafish. The otx2b gene is expressed in the developing hypothalamus, and otx2bhu3625/hu3625 fish exhibit multiple defects in the development of head structures and are not viable past 10 days post fertilization (dpf). Otx2bhu3625/hu3625 fish have a small hypothalamus and low expression of pituitary growth hormone and prolactin (prl). The gills of otx2bhu3625/hu3625 fish have weak sodium influx, consistent with the role of prolactin in osmoregulation. The otx2bhu3625/hu3625 eyes are microphthalmic with colobomas, which may underlie the inability of the mutant fish to find food. The small pituitary and eyes are associated with reduced cell proliferation and increased apoptosis evident at 3 and 5 dpf, respectively. These observations establish the zebrafish as a useful tool for the analysis of CPHD genes with variable and complex phenotypes.

  2020年06月, Human molecular genetics, 29(10) (10), 1648 - 1657, 英語, 国際誌

  研究論文（学術雑誌）


• Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma.

  Kentaro Suda, Hidenori Fukuoka, Yuto Yamazaki, Katsumi Shigemura, Miki Mukai, Yukiko Odake, Ryusaku Matsumoto, Hironori Bando, Michiko Takahashi, Genzo Iguchi, Masato Fujisawa, Masahiro Oka, Katsuhiko Ono, Kazuo Chihara, Hironobu Sasano, Wataru Ogawa, Yutaka Takahashi

  CONTEXT: Germline mutations in fumarate hydratase (FH) gene are known to cause hereditary leiomyomatosis and renal cell carcinoma (HLRCC) and are occasionally accompanied with cutaneous and uterine leiomyoma or cortisol-producing adrenocortical hyperplasia. However, the association between FH mutations and cardiac or adrenocortical tumors has remained unknown. Here, we identified a novel deletion in FH, exhibiting cardiac myxoma and subclinical Cushing syndrome due to adrenocortical tumor. CASE DESCRIPTION: A 44-year-old man was referred to our hospital for cardiac and adrenal tumor evaluation. He had a history of multiple painful, dermal papules and nodules diagnosed as cutaneous leiomyoma. The surgically resected cardiac tumor was diagnosed as myxoma. The adrenal tumor was clinically diagnosed as subclinical Cushing syndrome. Laparoscopically resected adrenal tumor was pathologically diagnosed as adrenocortical adenoma harboring unique histological findings similar to primary pigmented nodular adrenocortical disease (PPNAD). DNA analysis revealed a germline deletion in FH c0.737delT (p. Phe225Leufs*31) and loss of heterozygosity (LOH) in cardiac myxoma. As a functional analysis of FH in cardiac myxoma, low FH protein expression with elevated 2-succinocysteine (2SC), a marker of FH dysfunction, was immunohistochemically detected. However, in adrenocortical tumor, LOH of FH was not detected, and FH or 2SC expression was not altered. CONCLUSIONS: This is the first case of HLRCC complicated by cardiac myxoma. LOH of FH deletion and its dysfunction were identified in cardiac myxoma. The association between FH deletion and adrenocortical lesion, however, needs to be further clarified.

  2020年06月, The Journal of clinical endocrinology and metabolism, 105(6) (6), 英語, 国際誌

  研究論文（学術雑誌）


• SAT-291 SIX3 Is Essential for Hypothalamic and Pituitary Development

  Bando H, Brinkmeier M, Castinetti F, Gergics P, Mortensen A, Ozel A, Ma Q, Li J, Brue T, Camper S

  2020年05月, Journal of the Endocrine Society

  研究論文（学術雑誌）


• Autoimmune Pituitary Disease: New Concepts With Clinical Implications.

  Masaaki Yamamoto, Genzo Iguchi, Hironori Bando, Keitaro Kanie, Ryoko Hidaka-Takeno, Hidenori Fukuoka, Yutaka Takahashi

  Some endocrine disorders, including hypophysitis and isolated adrenocorticotropic hormone (ACTH) deficiency, are caused by an autoimmune response to endocrine organs. Although the pathogenesis of some autoimmune endocrine diseases has been elucidated, it remains obscure for most. Anti-PIT-1 hypophysitis (anti-PIT-1 antibody syndrome) is a newly described pituitary autoimmune disease characterized by acquired and specific growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies. This disorder is associated with a thymoma or neoplasm that ectopically expresses pituitary-specific transcription factor 1 (PIT-1) protein. Circulating anti-PIT-1 antibody is a disease marker, and PIT-1-reactive cytotoxic T cells (CTLs) play a pivotal role in disease development. In addition, isolated ACTH deficiency appears to be caused by autoimmunity to corticotrophs; however, the pathogenesis remains unclear. A recently described case of isolated ACTH deficiency with large cell neuroendocrine carcinoma (LCNEC) showed ectopically expressed proopiomelanocortin (POMC), and circulating anti-POMC antibody and POMC-reactive CTLs were also detected. As CTL infiltrations around corticotrophs were also observed, isolated ACTH deficiency may be associated at least in part with a paraneoplastic syndrome. Although several underlying mechanisms for pituitary autoimmunity have been proposed, these observations highlight the importance of paraneoplastic syndrome as a cause of pituitary autoimmune disease. In this review, we focus on the pathophysiology and connection of anti-PIT-1 hypophysitis and isolated ACTH deficiency and discuss the state-of-art knowledge for understanding pituitary autoimmunity.

  2020年04月, Endocrine reviews, 41(2) (2), 英語, 国際誌

  研究論文（学術雑誌）


• Congenital pituitary hypoplasia model demonstrates hypothalamic OTX2 regulation of pituitary progenitor cells.

  Ryusaku Matsumoto, Hidetaka Suga, Takashi Aoi, Hironori Bando, Hidenori Fukuoka, Genzo Iguchi, Satoshi Narumi, Tomonobu Hasegawa, Keiko Muguruma, Wataru Ogawa, Yutaka Takahashi

  Pituitary develops from oral ectoderm in contact with adjacent ventral hypothalamus. Impairment in this process results in congenital pituitary hypoplasia (CPH); however, there have been no human disease models for CPH thus far, prohibiting the elucidation of the underlying mechanisms. In this study, we established a disease model of CPH using patient-derived induced pluripotent stem cells (iPSCs) and 3D organoid technique, in which oral ectoderm and hypothalamus develop simultaneously. Interestingly, patient iPSCs with a heterozygous mutation in the orthodenticle homeobox 2 (OTX2) gene showed increased apoptosis in the pituitary progenitor cells, and the differentiation into pituitary hormone-producing cells was severely impaired. As an underlying mechanism, OTX2 in hypothalamus, not in oral ectoderm, was essential for progenitor cell maintenance by regulating LHX3 expression in oral ectoderm via FGF10 expression in the hypothalamus. Convincingly, the phenotype was reversed by the correction of the mutation, and the haploinsufficiency of OTX2 in control iPSCs revealed a similar phenotype, demonstrating that this mutation was responsible. Thus, we established an iPSC-based congenital pituitary disease model, which recapitulated interaction between hypothalamus and oral ectoderm and demonstrated the essential role of hypothalamic OTX2.

  2020年02月, The Journal of clinical investigation, 130(2) (2), 641 - 654, 英語, 国際誌

  研究論文（学術雑誌）


• Pathogenesis of Anti-PIT-1 Antibody Syndrome: PIT-1 Presentation by HLA Class I on Anterior Pituitary Cells.

  Keitaro Kanie, Hironori Bando, Genzo Iguchi, Keiko Muguruma, Ryusaku Matsumoto, Ryoko Hidaka-Takeno, Yasuhiko Okimura, Masaaki Yamamoto, Yasunori Fujita, Hidenori Fukuoka, Kenichi Yoshida, Kentaro Suda, Hitoshi Nishizawa, Wataru Ogawa, Yutaka Takahashi

  Context: Anti-pituitary-specific transcriptional factor-1 (anti-PIT-1) antibody syndrome is characterized by acquired and specific deficiencies in growth hormone, prolactin, and thyroid-stimulating hormone. Although PIT-1-reactive cytotoxic T lymphocytes (CTLs) have been speculated to recognize anterior pituitary cells and to cause the injury in the pathogenesis of the syndrome, it remains unclear whether endogenous PIT-1 protein is processed through the proteolytic pathway and presented as an antigen on anterior pituitary cells. Objective: To examine how PIT-1 protein is processed and whether its epitope is presented by major histocompatibility complex (MHC)/HLA class I on anterior pituitary cells. Materials and Methods: Immunofluorescence staining and proximity ligation assay (PLA) were performed using anti-PIT-1 antibody and patients' sera on PIT-1-expressing cell line GH3 cells and human induced pluripotent stem cell (iPSC)-derived pituitary tissues. Results: PIT-1 was colocalized with MHC class I molecules, calnexin, and GM130 in the cytosol. PLA results showed that PIT-1 epitope was presented by MHC/HLA class I molecules on the cell surface of GH3 cells and iPSC-derived pituitary cells. The number of PIT-1/HLA complexes on the cell surface of pituitary cells in the patient was comparable with that in the control subject. Conclusions: Our data indicate that PIT-1 protein is processed in the antigen presentation pathway and that its epitopes are presented by in MHC/HLA class I on anterior pituitary cells, supporting the hypothesis that PIT-1-reactive CTLs caused the cell-specific damage. It is also suggested that number of epitope presentation was not associated with the pathogenesis of anti-PIT-1 antibody syndrome.

  2019年11月, Journal of the Endocrine Society, 3(11) (11), 1969 - 1978, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.

  Kaori Hozumi, Hidenori Fukuoka, Yukiko Odake, Takehito Takeuchi, Tomoko Uehara, Takeshi Sato, Naoko Inoshita, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yushi Hirota, Genzo Iguchi, Masaaki Taniguchi, Naoki Otsuki, Chikako Nishigori, Kenjiro Kosaki, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahashi

  Although acromegaly has been reported in patients with Neurofibromatosis type 1 (NF1), these cases have not been associated with growth hormone (GH)-producing somatotroph adenoma, but with optic pathway glioma. A 68 year-old Japanese woman, who had been clinically diagnosed with NF1, was referred to our hospital due to a thyroid tumor and hypercalcemia. Acromegaly was suspected due to her facial features, and subsequent examinations revealed the presence of GH excess with a pituitary tumor, leading to the diagnosis of acromegaly. Histological and immunohistochemical analysis demonstrated an eosinophilic pituitary adenoma with diffuse positivity for GH, indicating typical somatotroph adenoma. In addition, her thyroid tumor was diagnosed histologically as follicular thyroid carcinoma (FTC) with primary hyperparathyroidism (PHPT). To investigate the pathogenesis of this untypical multiple endocrine tumor case of NF1, genetic analysis was performed using peripheral leukocytes and tissue of resected tumors. A heterozygous novel germline nonsense mutation (p.Arg1534*) in exon 35 of the NF1 gene was detected from peripheral leukocytes, which results in a truncated protein lacking the critical domain for GTPase activity, strongly suggesting its causal role in NF1. The loss of heterozygosity (LOH) in exon 35 of the NF1 gene was not detected in the somatotroph adenoma, parathyroid adenoma, and FTC. Although any mutations of the following genes; MEN1, CDKN1B, and PAX8-PPARγ were not detected, a heterozygous GNAS R201C mutation was detected in the somatotroph adenoma. To our knowledge, this is the first rare MEN1-like case of genetically diagnosed NF1 complicated with acromegaly caused by a somatotroph adenoma.

  2019年10月, Endocrine journal, 66(10) (10), 853 - 857, 英語, 国内誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• IgG4-related hypophysitis in patients with autoimmune pancreatitis.

  Keitaro Kanie, Hironori Bando, Genzo Iguchi, Hideyuki Shiomi, Atsuhiro Masuda, Hidenori Fukuoka, Hitoshi Nishizawa, Yasunori Fujita, Arata Sakai, Takashi Kobayashi, Yuuki Shiomi, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Yuzo Kodama, Wataru Ogawa, Yutaka Takahashi

  PURPOSE: IgG4-related disease involves various organs including the pituitary and pancreas. The prevalence of IgG4-related hypophysitis is relatively rare compared with IgG4-related pancreatitis (autoimmune pancreatitis). Although several cases demonstrating both autoimmune pancreatitis and hypophysitis have been reported, the prevalence of IgG4-related hypophysitis in patients with autoimmune pancreatitis remains unknown. This study aimed at screening for IgG4-related hypophysitis to accurately determine its prevalence in patients with autoimmune pancreatitis. METHODS: In this cohort study, we screened IgG4-related hypophysitis via pituitary magnetic resonance imaging (MRI) and endocrinological examination in 27 patients who were undergoing follow-up for autoimmune pancreatitis at Kobe University Hospital between 2014 and 2018. RESULTS: Among 27 patients with autoimmune pancreatitis, 5 patients exhibited morphological abnormalities in the pituitary (18.5%). Among them, one patient (3.7%) met the criteria for hypophysitis with an enlarged pituitary and stalk concomitant with hypopituitarism. After glucocorticoid treatment, the enlarged pituitary shrank and became empty sella during the clinical course. Four patients (14.8%) revealed empty sella without obvious pituitary dysfunction. Four of 5 patients with morphological pituitary abnormalities showed multiple organ involvement in addition to pancreatic and pituitary involvement. Accordingly, multiple organ involvement was more prevalent in patients with morphological pituitary abnormalities (80%) compared to those without (48%). CONCLUSIONS: Although a large-scale study is necessary to validate these results, these data suggest that the prevalence of hypophysitis in patients with autoimmune pancreatitis may be underestimated. Based on our findings, we recommend screening for hypophysitis, especially in patients with multiple organ involvement.

  2019年02月, Pituitary, 22(1) (1), 54 - 61, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome.

  Hironori Bando, Genzo Iguchi, Keitaro Kanie, Hitoshi Nishizawa, Ryusaku Matsumoto, Yasunori Fujita, Yukiko Odake, Kenichi Yoshida, Kentaro Suda, Hidenori Fukuoka, Keiko Tanaka, Wataru Ogawa, Yutaka Takahashi

  PURPOSE: In isolated adrenocorticoropic hormone (ACTH) deficiency (IAD), autoimmunity against corticotrophs has been suggested; however, the pathogenesis remains largely unknown. Large cell neuroendocrine carcinoma (LCNEC) of the lung is a pulmonary tumor of high-grade malignant neuroendocrine tumor and it reportedly caused paraneoplastic syndrome by autoimmunity in several cases. METHODS: A 42-year-old woman with isolated adrenocorticotropic (ACTH) hormone deficiency (IAD) was diagnosed with large cell neuroendocrine carcinoma (LCNEC) 3 years after being diagnosed with IAD. We hypothesized that the LCNEC played a causal role in the development of IAD as a paraneoplastic syndrome and analyzed the autoimmunity. We also analyzed another case of ectopic ACTH syndrome to prove this hypothesis. RESULTS: The LCNEC tissue revealed an ectopic ACTH expression and lymphocyte infiltration. Interestingly, autoantibody against the proopiomelanocortin (POMC) protein was detected in the peripheral blood. Although, patient's serum did not show any effects on cell viability, proliferation, nor pomc expression in a corticotroph cell line, AtT20 cells, patient's lymphocytes in the peripheral blood specifically reacted toward POMC protein, indicating a presence of cytotoxic T lymphocytes (CTLs). In addition, the analysis of another case of ectopic ACTH syndrome showed lymphocyte infiltration not only in the metastatic liver tumors but also in the pituitary. Moreover, most CD8-positive cells resided adjacent to corticotrophs. CONCLUSIONS: These data indicate that the ectopic ACTH expression in the tumor evoked the autoimmunity to corticotrophs and caused IAD as a form of paraneoplastic syndrome.

  2018年10月, Pituitary, 21(5) (5), 480 - 489, 英語, 国際誌

  研究論文（学術雑誌）


• 【内分泌症候群(第3版)-その他の内分泌疾患を含めて-】視床下部・下垂体 その他 抗PIT-1抗体症候群

  井口 元三, 坂東 弘教, 高橋 裕

  (株)日本臨床社, 2018年09月, 日本臨床, 別冊(内分泌症候群I) (内分泌症候群I), 234 - 238, 日本語


• Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects.

  Ryusaku Matsumoto, Masafumi Koga, Soji Kasayama, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Wataru Ogawa, Yutaka Takahashi

  BACKGROUND: Most of circulating IGF-I is derived from the liver and circulating IGF-I levels are decreased in several pathological conditions, such as liver cirrhosis, uncontrolled diabetes, renal failure, and malnutrition. However, it has not fully been elucidated which factors modify IGF-I level in a physiological condition. OBJECTIVE: To identify the factors which are associated with circulating IGF-I levels. DESIGN: Cross-sectional study. METHODS: This study included 428 subjects who undertook health check-up. Subjects diagnosed with non-alcoholic fatty liver disease (NAFLD) by ultrasonography were analyzed separately. Univariate and multivariate regression analyses were conducted to identify the factors associated with circulating IGF-I levels. RESULTS: Regression analyses revealed that serum albumin levels, total-bilirubin levels, calcium levels, and HOMA-IR were positively correlated with IGF-I levels. Serum transaminase levels and habitual drinking (ethanol intake >20 g/day) were negatively correlated with serum IGF-I levels. Although serum IGF-I standard deviation scores (SDS) in subjects with and without NAFLD were comparable, after adjusting confounding factors clarified by multivariate regression analysis, IGF-I SDS negatively correlated with the presence of NAFLD. CONCLUSION: In this study, we demonstrated that serum bilirubin and calcium levels are correlated with serum IGF-I levels. Although further study is necessary, these data suggest a presence of interaction between GH-IGF-I axis and bilirubin and calcium metabolism.

  2018年06月, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 40, 55 - 60, 英語, 国際誌

  研究論文（学術雑誌）


• 【自己免疫の関与する内分泌代謝疾患の最前線】下垂体機能低下症を呈する新たな疾患概念 抗PIT-1抗体症候群

  高橋 裕, 坂東 弘教, 井口 元三

  (株)最新医学社, 2018年05月, 最新医学, 73(5) (5), 627 - 632, 日本語


• 自己免疫性下垂体疾患における抗PIT-1抗体症候群の位置付けと病態

  井口 元三, 坂東 弘教, 高橋 裕

  (有)科学評論社, 2018年03月, 内分泌・糖尿病・代謝内科, 46(3) (3), 200 - 205, 日本語


• Two Cases of Atezolizumab-Induced Hypophysitis.

  Keitaro Kanie, Genzo Iguchi, Hironori Bando, Yasunori Fujita, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi

  Cancer immunotherapy has emerged as treatment of multiple advanced cancer types. Immune checkpoint inhibitors, namely anticytotoxic T-lymphocyte antigen-4 (CTLA-4), antiprogrammed cell death-1 (PD-1), and antiprogrammed cell death-1 ligand 1 (PD-L1) antibodies, have been used for treatment of various cancers. Classified as immune-related adverse events, several endocrinopathies, including hypophysitis, are associated with these agents. Although anti-CTLA-4-induced hypophysitis has been frequently observed, hypophysitis upon use of anti-PD-1 and anti-PD-L1 antibodies is rare. Case 1 is a 65-year-old man presented with a stage IV non-small cell lung cancer (NSCLC) treated with atezolizumab (an anti-PD-L1 antibody) following several inefficacious chemotherapies. After 56 weeks of the treatment, he complained of general malaise and appetite loss, and was diagnosed with adrenal insufficiency. Endocrinological examination revealed isolated adrenocorticotropic hormone (ACTH) deficiency; pituitary magnetic resonance imaging (MRI) showed anterior pituitary atrophy. Hydrocortisone replacement therapy rapidly improved his symptoms and enabled him to continue atezolizumab therapy. Case 2 is a 70-year-old man with a stage IV NSCLC treated with atezolizumab. After 52 weeks of treatment, he was diagnosed with isolated ACTH deficiency. Pituitary MRI revealed no obvious abnormalities in the anterior pituitary. Hydrocortisone replacement therapy was also efficacious. We report two cases of atezolizumab-induced hypophysitis. Both showed isolated ACTH deficiency, suggesting similar clinical characteristics of hypophysitis associated with the use of anti-PD-1 antibodies. These results suggest a caution for the late-onset central adrenal insufficiency associated with hypophysitis in patients treated with anti-PD-L1 antibodies.

  2018年01月, Journal of the Endocrine Society, 2(1) (1), 91 - 95, 英語, 国際誌

  神戸大学リポジトリ（Kernel）へのリンク


• Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience.

  Yukiko Odake, Hidenori Fukuoka, Masaaki Yamamoto, Yoshifumi Arisaka, Junya Konishi, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  PURPOSE: Acromegaly is a disease associated with an increased risk for several kinds of neoplasms including colon and thyroid cancer. Although the association between acromegaly and pancreatic neoplasms has not been elucidated, it has recently been reported that GNAS gene mutations were found in 58% of intraductal papillary mucinous neoplasms (IPMNs), which are representative pancreatic cystic lesions, suggesting a link between IPMNs and acromegaly. To assess the prevalence of pancreatic cystic lesions in patients with acromegaly, we performed a retrospective cross-sectional single institute study. METHODS: Thirty consecutive acromegalic patients (20 females and 10 males; mean age, 60.9 ± 11.9 years) who underwent abdominal contrast-enhanced computed tomography or magnetic resonance imaging between 2007 and 2015 at Kobe University Hospital were recruited. We also analyzed the relationship between presence of pancreatic cystic lesions and somatic GNAS mutations in pituitary tumors. RESULTS: Seventeen of 30 (56.7%) patients studied had pancreatic cystic lesions. Nine of 17 patients (52.9%) were diagnosed with IPMNs based on imaging findings. These results suggest that the prevalence of IPMNs may be higher in acromegalic patients in acromegalic patients than historically observed in control patients (up to 13.5%). In patients with pancreatic cystic lesions, the mean patient age was higher and the duration of disease was longer than in those without pancreatic cystic lesions (67.0 ± 2.3 vs. 53.0 ± 2.7 years, p < 0.001, 15.5 ± 2.4 vs. 7.3 ± 2.8 years, p = 0.04). There were no differences in serum growth hormone levels or insulin-like growth factor standard deviation scores between these two groups (21.3 ± 6.4 vs. 23.0 ± 7.4 ng/ml, p = 0.86, 6.6 ± 0.5 vs. 8.0 ± 0.6, p = 0.70). Neither the presence of somatic GNAS mutation in a pituitary tumor nor low signal intensity of the tumor in T2 weighted magnetic resonance imaging was associated with the presence of pancreatic cystic lesions. CONCLUSIONS: These data demonstrate that old or long-suffering patients with acromegaly have a higher prevalence of pancreatic cystic lesions. Moreover, the prevalence of pancreatic cystic lesions may be increased in acromegalic patients.

  2017年10月, Pituitary, 20(5) (5), 509 - 514, 英語, 国際誌

  研究論文（学術雑誌）


• A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.

  Hironori Bando, Genzo Iguchi, Yasuhiko Okimura, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Hidenori Fukuoka, Atsuko Mokubo, Katsuyoshi Tojo, Yoshimasa Maniwa, Wataru Ogawa, Yutaka Takahashi

  Anti-PIT-1 antibody syndrome has recently been reported and characterized by acquired growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies associated with autoimmunity to a pituitary specific transcription factor PIT-1, which plays an essential role in GH-, PRL-, and TSH-producing cells. Although circulating anti-PIT-1 antibody and PIT-1-reactive cytotoxic T cells (CTLs) were detected in the patients, the pathophysiology and precise mechanisms for the autoimmunity remain unclarified. During the follow up, thymoma was diagnosed in all 3 cases with anti-PIT-1 antibody syndrome. Immunohistochemical analysis revealed that PIT-1 was strongly expressed in neoplastic cortical thymic epithelial cells. Importantly, after thymectomy, the titer of anti-PIT-1 antibody decreased and reactivity of CTLs toward PIT-1 diminished. These data strongly suggest that the aberrant expression of PIT-1 in the thymoma plays a causal role in the development of this syndrome. Thus, we define that this syndrome is a novel thymoma-associated autoimmune disease.

  2017年02月, Scientific reports, 7, 43060 - 43060, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• 内科系症例検討 神経線維腫症I型に多彩な内分泌腫瘍を合併した先端巨大症の1例

  小武 由紀子, 福岡 秀規, 穂積 かおり, 佐藤 武志, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 長谷川 奉延, 小川 渉, 高橋 裕

  (株)ライフ・サイエンス, 2017年02月, Progress in Medicine, 37(2) (2), 292 - 293, 日本語


• A Novel Clinical Entity of Autoimmune Endocrinopathy: Anti-PIT-1 Antibody Syndrome.

  Genzo Iguchi, Hironori Bando, Yutaka Takahashi

  Pituitary-specific transcription factor 1 (PIT-1; POU domain, class 1, transcription factor 1 (POU1F1)) is an essential transcription factor for the differentiation of somatotrophs, lactotrophs, and thyrotrophs, and for the expression of growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH). Mutations in PIT-1 cause congenital defects in GH and PRL secretion and severe TSH insufficiency. Anti-PIT-1 antibody syndrome, firstly reported in 2011, is characterized by acquired GH, PRL, and TSH deficiencies without PIT-1 mutation and is associated with the presence of the circulating antibody against PIT-1 protein as a marker. Various autoantibodies are detected with multiple endocrine organopathies in this syndrome; therefore, it meets the criteria of autoimmune polyglandular syndrome. Mechanistically, cytotoxic T lymphocytes specifically reacting with PIT-1 protein play an important role in the development of this syndrome.

  2017年, Frontiers of hormone research, 48, 76 - 83, 英語, 国際誌

  研究論文（学術雑誌）


• Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations.

  Kenichi Yoshida, Hidenori Fukuoka, Yukiko Odake, Shinsuke Nakajima, Mariko Tachibana, Jun Ito, Yusei Hosokawa, Tomoko Yamada, Hiroshi Miura, Natsu Suematsu, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Wataru Ogawa, Yutaka Takahashi

  Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulness as a marker for monitoring medical therapy has not yet been established. The aim of this study was to assess the utility of multiple salivary cortisol measurements in patients with Cushing's syndrome (CS) during medical therapy. Six patients with CS (three with cortisol-secreting adrenocortical adenoma and three with ACTH-secreting pituitary adenoma) were recruited. Samples for morning serum cortisol, urinary free cortisol (UFC), and multiple salivary cortisol levels were collected before and during metyrapone treatment. The area under the curve (AUC) and mean value (MV) of daily salivary cortisol levels were calculated. In five out of six patients, UFC were normalized; however, multiple salivary cortisol measurements revealed an impaired diurnal cortisol rhythm in these patients. To verify the usefulness of multiple salivary cortisol measurements, we performed a prospective case study of a patient in whom the excess secretion of cortisol was not controlled (UFC 211 μg/day) with 2,250 mg/day in four divided doses of metyrapone. Multiple measurements of salivary cortisol revealed that cortisol levels elevated before the next administration. Accordingly, we shortened the interval by increasing the number of administration from four to five times per day, with a slight increment of daily dose of 2,500 mg. These optimizations resulted in a drastic improvement of diurnal pattern as well as UFC level (101 μg/day). Changes in both the MV and AUC of salivary cortisol levels were more correlated with those in UFC levels (Correlation coefficient 0.75, p = 0.007, and 0.70, p = 0.017) than those in the morning serum cortisol levels (0.42, p = 0.200), indicating that multiple salivary cortisol measurements reflect more precisely the excess secretion of cortisol. Our preliminary data suggest that multiple salivary cortisol measurements can be a useful tool to visualize the diurnal cortisol rhythm and to determine the dose and timing of metyrapone during the treatment in patients with CS.

  2017年, Frontiers in endocrinology, 8, 375 - 375, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma.

  Ryusaku Matsumoto, Masako Izawa, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  Most of acromegaly is caused by a sporadic somatotropinoma and a couple of novel gene mutations responsible for somatotropinoma have recently been reported. To determine the cause of sporadic somatotropinoma in Japanese patients, we analyzed 61 consecutive Japanese patients with somatotropinoma without apparent family history. Comprehensive genetic analysis revealed that 31 patients harbored guanine nucleotide-binding protein, alpha stimulating (GNAS) mutations (50.8%) and three patients harbored aryl hydrocarbon receptor interacting protein (AIP) mutations (4.9%). No patients had G protein-coupled receptor 101 (GPR101) mutations. The patients in this cohort study were categorized into three groups of AIP, GNAS, and others and compared the clinical characteristics. The AIP group exhibited significantly younger age at diagnosis, larger tumor, and higher nadir GH during oral glucose tolerance test. In all patients with AIP mutation, macro- and invasive tumor was detected and repetitive surgery or postoperative medical therapy was needed. One case showed a refractory response to postoperative somatostatin analogue (SSA) but after the addition of cabergoline as combined therapy, serum IGF-I levels were controlled. The other case showed a modest response to SSA and the switching to cabergoline monotherapy was also effective. These data suggest that although resistance to SSA has been reported in patients with AIP mutations, the response to dopamine agonist (DA) may be retained. In conclusion, the cause of sporadic somatotropinoma in Japanese patients was comparable with the previous reports in Caucasians, patients with AIP mutations showed unique clinical characteristics, and DA may be a therapeutic option for patients with AIP mutations.

  2016年11月, Endocrine journal, 63(11) (11), 953 - 963, 英語, 国内誌

  研究論文（学術雑誌）


• IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner.

  Hitoshi Nishizawa, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Kentaro Suda, Hironori Bando, Ryusaku Matsumoto, Kenichi Yoshida, Yukiko Odake, Wataru Ogawa, Yutaka Takahashi

  Hepatic fibrosis in nonalcoholic steatohepatitis (NASH) and cirrhosis determines patient prognosis; however, effective treatment for fibrosis has not been established. Oxidative stress and inflammation activate hepatic stellate cells (HSCs) and promote fibrosis. In contrast, cellular senescence inhibits HSCs' activity and limits fibrosis. The aim of this study was to explore the effect of IGF-I on NASH and cirrhotic models and to clarify the underlying mechanisms. We demonstrate that IGF-I significantly ameliorated steatosis, inflammation, and fibrosis in a NASH model, methionine-choline-deficient diet-fed db/db mice and ameliorated fibrosis in cirrhotic model, dimethylnitrosamine-treated mice. As the underlying mechanisms, IGF-I improved oxidative stress and mitochondrial function in the liver. In addition, IGF-I receptor was strongly expressed in HSCs and IGF-I induced cellular senescence in HSCs in vitro and in vivo. Furthermore, in mice lacking the key senescence regulator p53, IGF-I did not induce cellular senescence in HSCs or show any effects on fibrosis. Taken together, these results indicate that IGF-I induces senescence of HSCs, inactivates these cells and limits fibrosis in a p53-dependent manner and that IGF-I may be applied to treat NASH and cirrhosis.

  2016年10月, Scientific reports, 6, 34605 - 34605, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients.

  Kentaro Suda, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hitoshi Nishizawa, Hironori Bando, Kenichi Yoshida, Yukiko Odake, Michiko Takahashi, Kazuhiko Sakaguchi, Wataru Ogawa, Yutaka Takahashi

  OBJECTIVE: Although serum insulin like growth factor type 1 (IGF-I) levels are negatively correlated with hemoglobin A1c (HbA1c) in patients with type 1 diabetes, this correlation is controversial in patients with type 2 diabetes mellitus (T2DM) because of the influence of multiple factors including insulin secretion and obesity. The aim of this study was to evaluate the influence of T2DM on serum growth hormone (GH) and IGF-I levels in Japanese patients, who exhibited relatively low BMI compared with white patients in the previous studies. DESIGN: We retrospectively analysed 315 consecutive Japanese hospitalized patients with T2DM. We analysed factors correlated with changes in serum IGF-I levels and those related to diabetes. RESULTS: The median HbA1c was 8.7% (7.4-10.2) and the median body mass index (BMI) was 26.2kg/m(2) (23.1-29.7), which was relatively low compared with the previous studies. Overall, no correlations was found between serum GH or IGF-I levels and fasting plasma glucose (FPG) or HbA1c; however, when stratified by FPG and HbA1c levels, serum IGF-I levels were significantly lower in patients with FPG≥200mg/dL than in those with FPG<200mg/dL (p=0.039). In addition, serum IGF-I levels were significantly lower in patients with HbA1c≥12% than in those with HbA1c<12% (p=0.046). Multiple linear regression analysis revealed a positive correlation between fasting C-peptide levels and serum IGF-I levels (p=0.040), whereas no correlations was found for BMI, duration of T2DM, FPG levels, or HbA1c. Moreover, patients with improved HbA1c levels during the follow up period showed a significant increase in serum IGF-I levels. CONCLUSIONS: Serum IGF-I levels were significantly decreased in Japanese patients with uncontrolled T2DM, and impaired insulin secretion may be a mechanism underlying this effect. When diagnosing acromegaly in patients with uncontrolled diabetes, these factors should be taken into account.

  2016年08月, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 29, 4 - 10, 英語, 国際誌

  研究論文（学術雑誌）


• 抗PIT-1抗体症候群 下垂体機能低下症をきたすわが国発のあらたな疾患概念

  坂東 弘教, 井口 元三, 高橋 裕

  医歯薬出版(株), 2016年06月, 医学のあゆみ, 257(12) (12), 1256 - 1258, 日本語


• Prevalence of Simple Renal Cysts in Acromegaly.

  Masaaki Yamamoto, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Michiko Takahashi, Hitoshi Nishizawa, Kentaro Suda, Hironori Bando, Yutaka Takahashi

  Objective Various organs are known to be affected by the comorbidities of acromegaly. However, the involvement of renal structural comorbidities, such as cysts, has so far remained largely unknown. In this single-center study, we aimed to determine the prevalence and factors associated with simple renal cysts in Japanese patients with acromegaly. Methods A total of 71 consecutive patients with acromegaly were analyzed, who all underwent abdominal ultrasonography at diagnosis between 1986 and 2012 at Kobe University Hospital. Results Of these 71 patients, 23 (32.4%) exhibited simple renal cysts. Acromegalic patients with renal cysts tended to be significantly older, had a higher prevalence of smoking- and higher nadir growth hormone (GH) levels during the oral glucose tolerance test (OGTT) than did those without renal cysts. A multivariate logistic regression analysis showed age, smoking, and nadir GH to be independent factors associated with renal cysts. Interestingly, the number of renal cysts positively correlated with both the basal GH levels and nadir GH levels during OGTT (r=0.66, p<0.05 and r=0.70, p<0.05, respectively). In addition, the mean diameter of renal cysts positively correlated with the systolic blood pressure (r=0.84, p<0.005). Conclusion This is the first report to show the prevalence of simple renal cysts in patients with acromegaly. Elevated nadir GH levels during OGTT were found to be associated with an increased risk of simple renal cysts. Therefore, an excessive secretion of GH may be related to the development of renal cysts.

  2016年, Internal medicine (Tokyo, Japan), 55(13) (13), 1685 - 90, 英語, 国内誌

  研究論文（学術雑誌）


• The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.

  Kenichi Yoshida, Hidenori Fukuoka, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Genzo Iguchi, Wataru Ogawa, Susan M Webb, Yutaka Takahashi

  PURPOSE: To develop a Japanese version of the acromegaly quality of life (QoL) questionnaire (AcroQoL) and investigate the factors associated with impaired QoL in patients with acromegaly. METHODS: We developed a Japanese version of the AcroQoL by a forward-backward method and evaluated QoL in 38 patients with acromegaly who had been followed up at an outpatient clinic at Kobe University Hospital. Its reliability was examined with Cronbach's alpha and item-total correlations. Second examination was performed for concurrent validity by assessment of correlations with the Short Form-36 (SF-36) and longitudinal analysis of the AcroQoL in 25 patients. RESULTS: Cronbach's alpha and item-total correlations showed a range of 0.76-0.93 and 0.20-0.84, respectively, and significant correlations were found between the AcroQoL and the SF-36. Younger age and a history of radiotherapy were associated with worse total score by the multivariate linear regression analysis (p = 0.020 and p = 0.042, respectively). Intriguingly, in the biochemically-controlled group after the exclusion of patients who received radiotherapy, patients who underwent surgery alone exhibited a higher psychological (75.0 vs. 65.7 %, p = 0.036) and appearance (64.3 vs. 53.6 %, p = 0.036) score than those who are treating with pharmaceutical therapy. CONCLUSIONS: The reliability of the Japanese version of the AcroQoL was satisfactory. Younger age and a history of radiotherapy were associated with lower QoL in patients with acromegaly. In biochemically-controlled acromegaly, patients who underwent surgery alone exhibited better QoL than those under pharmaceutical therapy.

  2015年12月, Pituitary, 18(6) (6), 876 - 83, 英語, 国際誌

  研究論文（学術雑誌）


• A diagnostic pitfall in IgG4-related hypophysitis: infiltration of IgG4-positive cells in the pituitary of granulomatosis with polyangiitis.

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Taniguchi, Seiji Kawano, Miki Saitoh, Kenichi Yoshida, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Akio Morinobu, Eiji Kohmura, Wataru Ogawa, Yutaka Takahashi

  INTRODUCTION: Immunoglobulin (Ig) G4-related hypophysitis is an emerging clinical entity, which is characterized by an elevated serum IgG4 concentration and infiltration of IgG4-positive plasma cells in the pituitary. Although some criteria for its diagnosis have been proposed, they have not been fully established. In particular, differential diagnosis from secondary chronic inflammation including granulomatosis with polyangiitis (GPA) is difficult in some cases. We describe central diabetes insipidus with pituitary swelling exhibiting infiltration of IgG4-positive cells. PATIENT: A 43-year-old woman in the remission stage of GPA presented with sudden-onset polyuria and polydipsia. Pituitary magnetic resonance imaging revealed swelling of the anterior and posterior pituitary and stalk, with heterogeneous gadolinium enhancement and disappearance of the high signal intensity of the posterior pituitary. Evaluation of biochemical markers for GPA suggested that the disease activity was well-controlled. Endocrinological examination revealed the presence of central diabetes insipidus and growth hormone deficiency. Pituitary biopsy specimen showed IgG4-positive cells, with a 43% IgG4(+)/IgG(+) ratio, which met the criteria for IgG4-related hypophysitis. However, substantial infiltration of polymorphonuclear neutrophils with giant cells was also noted, resulting in a final diagnosis of pituitary involvement of GPA. CONCLUSION: These results suggest that pituitary involvement of GPA should be taken into account for the differential diagnosis of IgG4-related hypophysitis.

  2015年10月, Pituitary, 18(5) (5), 722 - 30, 英語, 国際誌

  研究論文（学術雑誌）


• The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study.

  Masaaki Yamamoto, Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Michiko Takahashi, Hitoshi Nishizawa, Kentaro Suda, Hironori Bando, Yutaka Takahashi

  PURPOSE: Colorectal neoplasms are well known to be a complication in cases of acromegaly; however, data on the prevalence of colorectal neoplasms in Asian patients with acromegaly are limited. Further, the factors associated with colorectal neoplasms in cases of acromegaly are controversial. Therefore, we aimed to clarify the prevalence of and factors associated with colorectal neoplasms in Japanese patients with acromegaly in a single center. METHODS: We analyzed consecutive 57 patients who had undergone full-length colonoscopy at the time of diagnosis at Kobe University Hospital between 1986 and 2012. RESULTS: Of the 57 patients, 22 (38.6%), 18 (31.6%) and 3 (5.3%) patients were diagnosed with hyperplastic polyps, adenomas, and adenocarcinomas, respectively and the prevalence was significantly higher than in a historical control group, Chinese patients with irritable bowel syndrome (The odds ratio was 4.0, 8.7, and 17.5, respectively). The prevalence of adenocarcinomas was also significantly higher in these patients than in the general Japanese population (odds ratio 14.5). Patients with acromegaly who had colorectal neoplasms had longer disease duration than those without colorectal neoplasms. Of note, the area under the growth hormone (GH) concentration-time curve (GH AUC) during the oral glucose tolerance test was significantly higher in patients with adenocarcinomas than in those with no colonic lesion or those with hyperplastic polyps. CONCLUSION: Japanese patients with acromegaly exhibited an increased risk of colorectal neoplasms, especially colorectal adenocarcinomas. An increased GH AUC was associated with an increased risk for colon adenocarcinomas in patients with acromegaly.

  2015年06月, Pituitary, 18(3) (3), 343 - 51, 英語, 国際誌

  研究論文（学術雑誌）


• [A Novel Clinical Entity "Anti-PIT-1 Antibody Syndrome"--Autoimmunity against a Transcription Factor].

  Yutaka Takahashi, Hironori Bando, Genzo Iguchi

  Autoimmunity against the pituitary has been observed in patients with hypophysitis. Although various autoantibodies against pituitary proteins have been reported, it is known that most of them are markers for the disease. Recently, a unique autoantibody against pituitary transcription factor PIT-1 (POU1F1) was detected in patients with an acquired combined pituitary hormone deficiency characterized by a specific defect in growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH). The antibody has been suggested to be involved in the pathogenesis because PIT-1 is an essential transcription factor that plays a role in the differentiation and maintenance of GH-, PRL-, and TSH-producing cells and mutations in the PIT-1 gene, resulting in a specific defect in these hormones. This syndrome was found to be a novel clinical entity; therefore, it was named 'anti-PIT-1 antibody syndrome'. Circulating anti-PIT-1 antibody and various autoantibodies were detected with multiple endocrine organopathy, meeting the definition of autoimmune polyglandular syndrome. Mechanistically, cytotoxic T lymphocytes that specifically react with PIT-1 protein play an important role in the development of this syndrome. In this review, we discuss the clinical aspects and pathophysiology of anti-PIT-1 antibody syndrome.

  2015年04月, Rinsho byori. The Japanese journal of clinical pathology, 63(4) (4), 491 - 7, 日本語, 国内誌

  研究論文（学術雑誌）


• Anti-PIT-1 antibody syndrome; a novel clinical entity leading to hypopituitarism.

  Hironori Bando, Genzo Iguchi, Masaaki Yamamoto, Ryoko Hidaka-Takeno, Yutaka Takahashi

  Various hypothalamic-pituitary diseases cause hypopituitarism. Inflammation related to autoimmunity also causes hypopituitarism. Hypophysitis is a representative disease caused by autoimmunity. Generally, anterior pituitary hormones are non-specifically impaired in this condition, but specific hormone defects have been reported in some cases. Anti-PIT-1 (pituitary-specific transcription factor 1) antibody syndrome is a novel clinical entity that presents an acquired combined pituitary hormone deficiency characterized by a specific defect in growth hormone, prolactin, and thyroid-stimulating hormone. Circulating anti-PIT-1 antibody along with various autoantibodies are detected with multiple endocrine organopathy, meeting the definition of autoimmune polyglandular syndrome. Mechanistically, cytotoxic T lymphocytes that specifically react with PIT-1 protein play an important role in the development of this syndrome.

  2015年03月, Pediatric endocrinology reviews : PER, 12(3) (3), 290 - 6, 英語, 国際誌

  研究論文（学術雑誌）


• The prevalence of acromegaly in hospitalized patients with type 2 diabetes.

  Kentaro Suda, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hitoshi Nishizawa, Hironori Bando, Ryusaku Matsumoto, Michiko Takahashi, Kazuhiko Sakaguchi, Yutaka Takahashi

  The prevalence of acromegaly is estimated to be 8-24/100,000, but several recent studies suggest it is underestimated. In particular, acromegaly is considered more prevalent in patients with type 2 diabetes mellitus (T2DM) than in the normal population. This study aimed to evaluate the prevalence of acromegaly in hospitalized patients with T2DM. A total of 327 hospitalized patients with T2DM were recruited as subjects. If serum insulin-like growth factor 1 (IGF-1) levels were found to be elevated, random GH level was measured or oral glucose tolerance test (OGTT) was performed. Five patients with elevated serum IGF-1 levels and random GH level or inadequate suppression of GH in the OGTT underwent pituitary magnetic resonance imaging. Of those patients, pituitary adenoma was detected in 2 patients. These 2 patients were diagnosed with acromegaly, as they also exhibited mild acromegalic features. Intriguingly, both these patients exhibited severe macroangiopathy and an absence of microangiopathy. The prevalence of acromegaly in the hospitalized patients with T2DM in this study was therefore 0.6%, suggesting a higher prevalence than that predicted. Although a large-scale prospective study is required to clarify the precise prevalence of acromegaly in hospitalized patients with T2DM, the present study shows that it is useful to screen hospitalized patients with T2DM for acromegaly by measuring their serum IGF-1 level.

  2015年, Endocrine journal, 62(1) (1), 53 - 9, 英語, 国内誌

  研究論文（学術雑誌）


• Accelerated Telomere Shortening in Acromegaly; IGF-I Induces Telomere Shortening and Cellular Senescence.

  Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yukiko Odake, Kenichi Yoshida, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Shozo Yamada, Wataru Ogawa, Yutaka Takahashi

  OBJECTIVE: Patients with acromegaly exhibit reduced life expectancy and increased prevalence of age-related diseases, such as diabetes, hypertension, and cardiovascular disease. However, the underlying mechanism has not been fully elucidated. Telomere shortening is reportedly associated with reduced life expectancy and increased prevalence of these age-related diseases. METHODS: We measured telomere length in patients with acromegaly using quantitative PCR method. The effect of GH and IGF-I on telomere length and cellular senescence was examined in human skin fibroblasts. RESULTS: Patients with acromegaly exhibited shorter telomere length than age-, sex-, smoking-, and diabetes-matched control patients with non-functioning pituitary adenoma (0.62 ± 0.23 vs. 0.75 ± 0.35, respectively, P = 0.047). In addition, telomere length in acromegaly was negatively correlated with the disease duration (R2 = 0.210, P = 0.003). In vitro analysis revealed that not GH but IGF-I induced telomere shortening in human skin fibroblasts. Furthermore, IGF-I-treated cells showed increased senescence-associated β-galactosidase activity and expression of p53 and p21 protein. IGF-I-treated cells reached the Hayflick limit earlier than GH- or vehicle-treated cells, indicating that IGF-I induces cellular senescence. CONCLUSION: Shortened telomeres in acromegaly and cellular senescence induced by IGF-I can explain, in part, the underlying mechanisms by which acromegaly exhibits an increased morbidity and mortality in association with the excess secretion of IGF-I.

  2015年, PloS one, 10(10) (10), e0140189, 英語, 国際誌

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.

  Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Hitoshi Nishizawa, Hironori Bando, Kentaro Suda, Michiko Takahashi, Yutaka Takahashi

  OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are frequently observed in patients with adult growth hormone deficiency (AGHD) and short-term GH replacement therapy (GHRT) has reportedly been efficacious in NAFLD and NASH. The aim of this study was to investigate whether long-term GHRT is an effective treatment for the hepatic comorbidities in AGHD. DESIGN: This is a retrospective observational study. We recruited 54 consecutive hypopituitary patients with AGHD. Among them, 31 patients who had received GHRT for more than 24 months were compared with 19 age- and sex-matched patients without GHRT. We also analyzed the long term effect of GHRT on 14 patients diagnosed with NASH by liver biopsy. In addition, we subdivided the GHRT group into GH-responder and GH-non-responder groups and analyzed the factors associated with the efficacy of the treatment. RESULTS: For a period of 24 months, the significant reduction of serum liver enzyme levels and a fibrotic marker was observed in patients receiving GHRT compared with the control group. Furthermore, GHRT also improved liver enzyme levels in AGHD patients with NASH. The GH-non-responder group showed a higher proportion of patients who gained weight during the study period. CONCLUSIONS: These results indicate that GHRT is efficacious for improving serum liver enzyme levels for at least 24 months in patients with AGHD. To optimize this effect, it is important to avoid body weight gain during the treatment.

  2014年10月, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 24(5) (5), 174 - 9, 英語, 国際誌

  研究論文（学術雑誌）


• Involvement of PIT-1-reactive cytotoxic T lymphocytes in anti-PIT-1 antibody syndrome.

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Yamamoto, Ryoko Hidaka-Takeno, Yasuhiko Okimura, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Katsuyoshi Tojo, Yutaka Takahashi

  CONTEXT: Anti-pituitary-specific transcriptional factor 1 (PIT-1) antibody syndrome is characterized by acquired growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) deficiencies associated with circulating anti-PIT-1 antibodies. Although autoimmunity to PIT-1 has been suggested as a pathogenesis, the precise mechanism of the syndrome remains unclarified. OBJECTIVE: To elucidate the involvement of antibody- or cell-mediated immunity in anti-PIT-1 antibody syndrome. MATERIALS AND METHODS: To investigate a direct effect of anti-PIT-1 antibody on pituitary cells, cell proliferation, and cytotoxicity detection assays were performed using patient serum. Enzyme-linked immunospot (ELISpot) assay was performed to evaluate the involvement of PIT-1-reactive cytotoxic T lymphocytes (CTLs). An immunohistochemical analysis using anti-CD4 or anti-CD8 antibody was performed to examine tissue infiltration by CTLs. RESULTS: Patient serum did not exhibit any inhibitory effect on cell proliferation and secretion of GH and PRL in GH3 cells. In addition, complement-dependent cytotoxicity was not detected in patient serum on GH3 cells or primary pituitary cells. The ELISpot assay revealed the presence of CTLs that specifically reacted to the recombinant PIT-1 protein in the patient's peripheral lymphocytes. CD8(+) cell infiltrations, which is the characteristic of CTLs, were observed in the pituitary gland, adrenal gland, stomach, thyroid gland, liver, and pancreas of the patient with anti-PIT-1 antibody syndrome. CONCLUSIONS: These results suggest that the anti-PIT-1 antibody is not a cause but a marker of anti-PIT-1 antibody syndrome, in which CTLs play a pivotal role in the pathogenesis.

  2014年09月, The Journal of clinical endocrinology and metabolism, 99(9) (9), E1744-9, 英語, 国際誌

  研究論文（学術雑誌）


• ErbB Mediate ACTH Suppression By Canertinib in Human Pituitary Corticotroph Adenoma Cells

  Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Song-Guang Ren, Shozo Yamada, Yutaka Takahashi

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3), 英語

  [査読有り]


• ErbB Mediate ACTH Suppression By Canertinib in Human Pituitary Corticotroph Adenoma Cells

  Hidenori Fukuoka, Genzo Iguchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Naoko Inoshita, Song-Guang Ren, Shozo Yamada, Yutaka Takahashi

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3), 英語

  [査読有り]


• IGF-I Ameliorates Hepatic Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis and Cirrhosis By Inhibiting the Hepatic Stellate Cell Activity

  Hitoshi Nishizawa, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Kentaro Suda, Hironori Bando, Ryusaku Matsumoto, Yutaka Takahashi

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3), 英語

  [査読有り]


• Acromegaly Is Associated with a Shortened Telomere Length

  Matsumoto Ryusaku, Fukuoka Hidenori, Iguchi Genzo, Bando Hironori, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Yamada Shozo, Takahashi Yutaka

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3)

  [査読有り]


• The Increased Area Under the Growth Hormone Concentration-Time Curve during Oral Glucose Tolerance Test Is Associated with Colorectal Adenocarcinoma in Acromegaly

  Yamamoto Masaaki, Fukuoka Hidenori, Iguchi Genzo, Matsumoto Ryusaku, Takahashi Michiko, Nishizawa Hitoshi, Suda Kentaro, Bando Hironori, Takahashi Yutaka

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3)

  [査読有り]


• The Characteristics of IgG4-Related Hypophysitis; A Comparison with Autoimmune Hypophysitis

  Bando Hironori, Iguchi Genzo, Fukuoka Hidenori, Matsumoto Ryusaku, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Takahashi Yutaka

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3)

  [査読有り]


• A Case of Androgen- and Fibroblast Growth Factor 23-Producing Ovarian Tumor

  Iguchi Genzo, Matsumoto Ryusaku, Bando Hironori, Suda Kentaro, Nishizawa Hitoshi, Takahashi Michiko, Fukuoka Hidenori, Imanishi Yasuo, Sasano Hironobu, Takahashi Yutaka

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3)

  [査読有り]


• The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature.

  Hironori Bando, Genzo Iguchi, Hidenori Fukuoka, Masaaki Taniguchi, Masaaki Yamamoto, Ryusaku Matsumoto, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Eiji Kohmura, Yutaka Takahashi

  OBJECTIVE: The prevalence and clinical characteristics of IgG4-related hypophysitis remain unclear due to the limited number of case reports. Therefore, in this study, we screened consecutive outpatients with hypopituitarism and/or diabetes insipidus (DI) to estimate its prevalence. METHODS: A total of 170 consecutive outpatients with hypopituitarism and/or central DI were screened at Kobe University Hospital for detecting IgG4-related hypophysitis by pituitary magnetic resonance imaging, measuring serum IgG4 concentrations, assessing the involvement of other organs, and carrying out an immunohistochemical analysis to detect IgG4-positive cell infiltration. RESULTS: Among the screened cases, 116 cases were excluded due to diagnosis of other causes such as tumors and congenital abnormalities. Additionally, 22 cases with isolated ACTH deficiency were analyzed and were found not to meet the criteria of IgG4-related hypophysitis. The remaining 32 cases were screened and seven were diagnosed with IgG4-related hypophysitis, of which three cases were diagnosed by analyzing pituitary specimens. IgG4-related hypophysitis was detected in 30% (seven of 23 patients) of hypophysitis cases and 4% of all hypopituitarism/DI cases. The mean age at the onset of IgG4-related hypophysitis was 61.8±8.8 years, and the serum IgG4 concentration was 191.1±78.3 mg/dl (normal values 5-105 mg/dl and values in IgG4-related disease (RD) ≥135 mg/dl). Pituitary gland and/or stalk swelling was observed in six patients, and an empty sella was observed in one patient. Multiple co-existing organ involvement was observed in four of the seven patients prior to the onset of IgG4-related hypophysitis. CONCLUSION: These data suggest that the prevalence of IgG4-related hypophysitis has been underestimated. We should also consider the possibility of the development of hypopituitarism/DI caused by IgG4-related hypophysitis during the clinical course of other IgG4-RDs.

  2014年02月, European journal of endocrinology, 170(2) (2), 161 - 72, 英語, 国際誌

  研究論文（学術雑誌）


• A missense single-nucleotide polymorphism in the sialic acid acetylesterase (SIAE) gene is associated with anti-PIT-1 antibody syndrome.

  Masaaki Yamamoto, Genzo Iguchi, Hironori Bando, Hidenori Fukuoka, Kentaro Suda, Michiko Takahashi, Hitoshi Nishizawa, Ryusaku Matsumoto, Katsuyoshi Tojo, Atsuko Mokubo, Tsutomu Ogata, Yutaka Takahashi

  A novel clinical entity related to autoimmune polygladular syndrome (APS) termed "anti-PIT-1 antibody syndrome" is characterized by a presence of circulating autoantibody against the pituitary-specific transcriptional factor-1 (PIT-1) with acquired specific defect in GH, PRL, and TSH. Although autoimmunity to PIT-1 has been suggested, the underlying mechanisms remain to be elucidated. Sialic acid acetylesterase (SIAE) plays a crucial role in regulating the threshold of autoantibody production of B-cells and the defective variants of SIAE are associated with an increased risk of various autoimmune diseases such as type 1 diabetes (T1DM). To explore the link between anti-PIT-1 antibody syndrome and SIAE, we analyzed SIAE gene in 3 patients with anti-PIT-1 antibody syndrome and 200 healthy control subjects, and compared the prevalence of single nucleotide polymorphisms. Intriguingly, we found A467V SIAE variants (c.1400C>T, rs7941523) in a heterozygous state in all the patients with anti-PIT-1 antibody syndrome, while we detected in 6 % of control subjects, in which the prevalence was significantly increased in the patients (P<0.0005). Considering the physiological function of SIAE and the clinical features of anti-PIT-1 antibody syndrome, present data imply a novel aspect of the pathogenesis in this disease.

  2014年, Endocrine journal, 61(6) (6), 641 - 4, 英語, 国内誌

  研究論文（学術雑誌）


• D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing's syndrome.

  Hidenori Fukuoka, Takehito Takeuchi, Ryusaku Matsumoto, Hironori Bando, Kentaro Suda, Hitoshi Nishizawa, Michiko Takahashi, Yushi Hirota, Genzo Iguchi, Yutaka Takahashi

  Venous thromboembolism (VTE) is frequently associated with hypercortisolemia. This retrospective single-center study aimed to clarify the significance of plasma D-dimer levels for VTE screening in patients with subclinical or overt Cushing's syndrome (soCS). A total of 72 consecutive treatment-naïve patients with soCS diagnosed at Kobe University Hospital between 2002 and 2014 were enrolled. Patients with both lower extremity ultrasound and D-dimer measurement data (n = 19) were recruited in study 1 and divided into 2 groups, a deep vein thrombosis (DVT) (-) group (n = 12) and DVT (+) group (n = 7) for a comparison of the associated factors. The age and D-dimer levels were higher in the DVT (+) group than in the DVT (-) group (p = 0.04 and 0.02, respectively). A receiver operating characteristic analysis found that D-dimer level ≥2.6 μg/mL correlated with the presence of DVT (sensitivity, 100%; specificity, 91.7%). Next, patients with D-dimer measurement data (n = 36) were recruited in study 2 and divided into 2 groups according to D-dimer level: D-dimer (-), <1 μg/mL group (n = 23) and D-dimer (+), ≥1 μg/mL group (n = 13); the groups were compared with respect to various VTE-related risk factors. A logistic regression analysis revealed that elevated cortisol level after low-dose dexamethasone suppression was a significant risk factor for D-dimer elevation (OR = 1.21, p = 0.02). In conclusion, these data demonstrate that a D-dimer level ≥2.6 μg/mL is an indicator of DVT in treatment naïve patients with soCS and suggests that relatively high autonomous cortisol secretion may be associated with thrombus formation.

  2014年, Endocrine journal, 61(10) (10), 1003 - 10, 英語, 国内誌

  研究論文（学術雑誌）


• SIRT1 regulates adaptive response of the growth hormone--insulin-like growth factor-I axis under fasting conditions in liver.

  Masaaki Yamamoto, Genzo Iguchi, Hidenori Fukuoka, Kentaro Suda, Hironori Bando, Michiko Takahashi, Hitoshi Nishizawa, Susumu Seino, Yutaka Takahashi

  Adaptation under fasting conditions is critical for survival in animals. Sirtuin 1 (SIRT1), a protein deacetylase, plays an essential role in adaptive metabolic and endocrine responses under fasting conditions by modifying the acetylation status of various proteins. Fasting induces growth hormone (GH) resistance in the liver, leading to decreased serum insulin-like growth factor-I (IGF-I) levels as an endocrine adaptation for malnutrition; however, the underlying mechanisms of this action remain to be fully elucidated. Here we report that in vivo knockdown of SIRT1 in the liver restored the fasting-induced decrease in serum IGF-I levels and enhanced the GH-dependent increase in IGF-I levels, indicating that SIRT1 negatively regulates GH-dependent IGF-I production in the liver. In vitro analysis using hepatocytes demonstrated that SIRT1 suppresses GH-dependent IGF-I expression, accompanied by decreased tyrosine phosphorylation on signal transducer and activator of transcription (STAT) 5. GST pull-down assays revealed that SIRT1 interacts directly with STAT5. When the lysine residues adjacent to the SH2 domain of STAT5 were mutated, STAT5 acetylation decreased concomitant with a decrease in its transcriptional activity. Knockdown of SIRT1 enhanced the acetylation and GH-induced tyrosine phosphorylation of STAT5, as well as the GH-induced interaction of the GH receptor with STAT5. These data indicate that SIRT1 negatively regulates GH-induced STAT5 phosphorylation and IGF-I production via deacetylation of STAT5 in the liver. In addition, our findings explain the underlying mechanisms of GH resistance under fasting conditions, which is a known element of endocrine adaptation during fasting.

  2013年09月, Proceedings of the National Academy of Sciences of the United States of America, 110(37) (37), 14948 - 53, 英語, 国際誌

  研究論文（学術雑誌）


• A case of transverse sinus thrombosis resulting in sensory aphasia in a patient with poorly controlled type 2 diabetes

  Bando, H., Yamada, H., Omori, Y., Tsuchihashi, D., Higo, S., Nishioka, C., Kitagaki, K.

  2013年, Journal of the Japan Diabetes Society, 56(3) (3)

  研究論文（学術雑誌）


• 粟粒結核を発症しARDSを呈したが救命し得た透析患者の一例

  橋口 由香里, 小中 義禎, 谷川 明, 芳野 啓, 田中 義和, 播 悠介, 藤永 潤, 正木 幸作, 坂東 弘教, 廣部 真由美, 片山 茂明, 上浦 望, 村田 成正, 芳野 弘, 深津 泰英, 後藤 格, 大久保 美歩, 野中 英美, 福永 馨, 八木 規夫, 森田 宗孝, 坂井 誠, 宮崎 宣弘, 谷 聡, 老籾 宗忠, 松岡 彰, 山本 清子, 岡田 志緒子, 藤森 明

  (一財)甲南病院, 2011年04月, 甲南病院医学雑誌, 28, 10 - 13, 日本語


• Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis.

  Hironori Bando, Naoko Hashimoto, Yushi Hirota, Kazuhiko Sakaguchi, Itoko Hisa, Yoshifumi Inoue, Yasuo Imanishi, Susumu Seino, Hiroshi Kaji

  A 49-year-old woman was admitted to our hospital for back pain with marked thoracic and extremity deformities leading to bed-rest for three years. She was diagnosed with hypophosphatemic osteomalacia based on her symptoms, X-ray and bone scintigram, high serum alkaline phosphatase level, and low serum levels of both phosphorus and 1,25 dihydroxyvitamin D(3) with inhibition of phosphorus reabsorption. Fanconi syndrome with renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis were related to the pathogenesis of osteomalacia in this case. Several causal diseases may be concomitantly responsible for acceleration of the severity of osteomalacia in this patient.

  2009年, Internal medicine (Tokyo, Japan), 48(5) (5), 353 - 8, 英語, 国内誌

  研究論文（学術雑誌）

• ハイブリッドクローズドループ(HCL)療法下でフルマラソンを完走した1型糖尿病の2例

  乾 妃那, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 84 - 84, 日本語


• 多職種連携のもとで実施した減量・代謝改善手術4例の経験

  芳野 啓, 廣田 勇士, 裏川 直樹, 山木 愛久, 西影 星二, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 85 - 85, 日本語


• 緩徐な経過を辿った免疫関連副作用(irAE)による1型様の糖尿病の1例

  齋藤 修一郎, 芳野 啓, 小畠 正樹, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 89 - 89, 日本語


• 複数の膵島関連自己抗体が陽性だがprobable判定であった緩徐進行1型糖尿病の1例

  湯川 恒弘, 深澤 圭似子, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2024年02月, 糖尿病, 67(2) (2), 102 - 102, 日本語


• コルチゾール暴露環境がコルチコトロフ腫瘍における免疫細胞浸潤に与える影響

  神澤真紀, 志智大城, 蟹江慶太郎, 山本雅昭, 山本直希, 辻本泰貴, 坂東弘教, 井口元三, 北野滋久, 井下尚子, 山田正三, 小川渉, 伊藤智雄, 福岡秀規

  2024年, ACTH Related Peptides (CD-ROM), 35


• コルチゾール暴露環境がコルチコトロフ腫瘍における免疫細胞浸潤に与える影響

  神澤真紀, 志智大成, 蟹江慶太郎, 山本雅昭, 山本直希, 辻本泰貴, 坂東弘教, 井口元三, 北野滋久, 井下尚子, 山田正三, 小川渉, 伊藤智雄, 福岡秀規

  2024年, 間脳・下垂体・副腎系研究会プログラム・抄録集(Web), 35th


• Down症候群に合併したACTH単独欠損症の一例

  渡邊美季, 浦井伸, 坂東弘教, 山本雅昭, 福岡秀規, 小川渉, 井口元三, 井口元三

  2024年, 日本内分泌学会雑誌, 100(1) (1)


• ACTH産生下垂体腫瘍におけるWW-like領域を含めたUSP8体細胞変異の解析

  辻本泰貴, 山本直希, 福嶋俊明, 柿原慧遵, 大町侑香, 本村悠馬, 大井佑夏, 佐々木百合子, 鈴木正暉, 浦井伸, 坂東弘教, 山本雅昭, 井口元三, 駒田雅之, 西岡宏, 山田正三, 小川渉, 福岡秀規

  2024年, 日本内分泌学会雑誌, 100(1) (1)


• GH,PRL完全欠損に至る過程を観察し得た抗PIT-1下垂体炎

  友藤清爾, 浦井伸, 坂東弘教, 神澤真紀, 山本雅昭, 福岡秀規, 津田政広, 井口元三, 井口元三, 小川渉

  2024年, 日本内分泌学会雑誌, 100(1) (1)


• SAP療法における基礎インスリン設定量とHLC導入後の基礎インスリン注入量の比較検討

  西垣 智子, 山本 あかね, 芳野 啓, 上田 真莉子, 松岡 敦子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  日本先進糖尿病治療研究会, 2023年11月, 日本先進糖尿病治療研究会雑誌, 17(2) (2), 92 - 92, 日本語


• Bilateral Suppressionを呈したアルドステロン産生腺腫の一例

  西垣 智子, 山本 雅昭, 樋口 雄一, 芳野 啓, 坂東 弘教, 松代 啓吾, 元津 倫幸, 祖父江 慶太郎, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 561 - 561, 日本語


• 家族性PBMAHを呈したARMC5_p.R173*ヘテロ接合型の1例

  樋口 雄一, 坂東 弘教, 芳野 啓, 山本 雅昭, 高橋 路子, 臼井 健, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 561 - 561, 日本語


• ラトケ嚢胞における染色マーカーの有用性と臨床像の関連

  佐々木 百合子, 坂東 弘教, 神澤 真紀, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 井口 元三, 山本 雅昭, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, 日本語


• 偽性Cushing症候群から発見に至ったNR3C1新規変異の一例

  山本 直希, 木戸 希, 坂東 弘教, 山本 雅昭, 浦井 伸, 辻本 泰貴, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 569 - 569, 日本語


• メチラポン漸増時にPCP増悪を認めたクッシング病疑いの一例

  木戸 希, 山本 雅昭, 坂東 弘教, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 581 - 581, 日本語


• 74歳で診断に至ったSCS合併Sheehan症候群の一例

  草壁 明日香, 坂東 弘教, 山本 雅昭, 芳野 啓, 廣田 勇士, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 587 - 587, 日本語


• 当院におけるAGHDに対するGHRTの長期効果および安全性の検討

  大井 佑夏, 山本 雅昭, 大町 侑香, 本村 悠馬, 辻本 泰貴, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 坂東 弘教, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 590 - 590, 日本語


• 染色体、薬剤、環境の複合的な寄与が考えられた骨粗鬆症の一例

  友藤 清爾, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 608 - 608, 日本語


• クッシング症候群におけるメチラポン単回投与への反応性の検討

  辻本 泰貴, 山本 雅昭, 坂東 弘教, 山本 直希, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 鈴木 正暉, 浦井 伸, 高橋 路子, 井口 元三, 小川 渉, 福岡 秀規

  (一社)日本内分泌学会, 2023年10月, 日本内分泌学会雑誌, 99(2) (2), 622 - 622, 日本語


• 免疫チェックポイント阻害薬が惹起した腫瘍随伴性ACTH単独欠損症

  渡邊 美季, 浦井 伸, 坂東 弘教, 本村 悠馬, 神澤 真紀, 立原 素子, 山本 雅昭, 福岡 秀規, 井口 元三, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 295 - 295, 日本語


• ゲル濾過分析でACTHの性状を確認し得た異所性ACTH産生腫瘍の一例

  中辻 萌, 坂東 弘教, 山本 雅昭, 芳野 啓, 松田 琢磨, 辻本 泰貴, 本村 悠馬, 土井 健史, 田中 雄悟, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 296 - 296, 日本語


• 血中に大分子ACTH分泌を認めたコルチゾール産生副腎腺腫の一例

  一ノ瀬 祐人, 中辻 萌, 坂東 弘教, 山本 雅昭, 芳野 啓, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 301 - 301, 日本語


• 抗PIT-1下垂体炎新規2例を加えた9症例の臨床的特徴

  浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 大井 佑夏, 樫谷 悠也, 飯田 啓二, 神澤 真紀, 福岡 秀規, 井口 元三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 311 - 311, 日本語


• ラトケ嚢胞の病理学的診断におけるKRT8の有用性

  佐々木 百合子, 坂東 弘教, 福原 紀章, 西岡 宏, 山田 正三, 浦井 伸, 本村 悠馬, 大町 侑香, 辻本 泰貴, 大井 佑夏, 鈴木 正暉, 山本 直希, 井口 元三, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 332 - 332, 日本語


• PPGLの周術期におけるメチロシン併用に関する検討

  大町 侑香, 山本 雅昭, 坂東 弘教, 巻野 将平, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(1) (1), 336 - 336, 日本語


• 骨粗鬆症を契機に診断に至ったLoeys-Dietz症候群の一例

  辻本 泰貴, 山本 直希, 福満 隼人, 坂東 弘教, 山本 雅昭, 廣田 勇士, 田中 敬子, 森貞 直哉, 長坂 美和子, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 29 - 31, 日本語


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年05月, 日本内分泌学会雑誌, 99(Suppl.Update) (Suppl.Update), 51 - 54, 日本語


• GAD抗体,IA-2抗体重複陽性であった緩徐進行1型糖尿病の1例

  永野 浩平, 本村 悠馬, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2023年04月, 糖尿病, 66(4) (4), 292 - 292, 日本語


• 残存インスリン時間の調整が低血糖減少に有効であったHCL加療中1型糖尿病の1例

  黒川 晟, 芳野 啓, 大町 侑香, 上田 真莉子, 山本 あかね, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2023年04月, 糖尿病, 66(4) (4), 307 - 307, 日本語


• 副鼻腔腫瘍として発見された下垂体腺腫の一例

  神澤 真紀, 藤田 祐一, 坂東 弘教

  (一社)日本内分泌学会, 2023年03月, 日本内分泌学会雑誌, 98(5) (5), 1624 - 1624, 日本語


• 妊娠中に成長ホルモン補充療法の再開を要したPIT-1異常症の1例

  辻本 泰貴, 坂東 弘教, 山本 雅昭, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 山本 直希, 鈴木 正暉, 浦井 伸, 井口 元三, 高橋 路子, 栖田 園子, 尾崎 可奈, 出口 雅士, 洪 聖暖, 坊 亮輔, 粟野 宏之, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年02月, 日本内分泌学会雑誌, 98(4) (4), 1035 - 1035, 日本語


• 妊娠中に成長ホルモン補充療法の再開を要したPIT-1異常症の1例

  辻本 泰貴, 坂東 弘教, 山本 雅昭, 大町 侑香, 本村 悠馬, 大井 佑夏, 佐々木 百合子, 山本 直希, 鈴木 正暉, 浦井 伸, 井口 元三, 高橋 路子, 栖田 園子, 尾崎 可奈, 出口 雅士, 洪 聖暖, 坊 亮輔, 粟野 宏之, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2023年02月, 日本内分泌学会雑誌, 98(4) (4), 1035 - 1035, 日本語


• 偽性Cushing症候群を契機に同定に至ったNR3C1新規変異の一例

  山本直希, 木戸希, 坂東弘教, 山本雅昭, 浦井伸, 辻本泰貴, 大町侑香, 本村悠馬, 大井佑夏, 佐々木百合子, 鈴木正暉, 高橋路子, 井口元三, 井口元三, 小川渉, 福岡秀規

  2023年, 日本神経内分泌学会学術集会プログラム・抄録集, 49th


• ODP329 Long-term Effect of Daily Growth Hormone Replacement Therapy on Glucose Tolerance in Adult growth Hormone Deficiency

  Hironori Bando, Hidenori Fukuoka, Genzo Iguchi, Keitaro Kanie, Wataru Ogawa, Hiroki Shichi, Masaki Suzuki, Michiko Takahashi, Yutaka Takahashi, Shin Urai, Naoki Yamamoto, Yuka Oi, Masaaki Yamamoto, Yuriko Sasaki

  The Endocrine Society, 2022年11月01日, Journal of the Endocrine Society, 6(Supplement{\_}1) (Supplement{\_}1), A499 - A500


• 骨粗鬆症を契機に診断に至ったLoeys-Dietz症候群の一例

  辻本 泰貴, 山本 直希, 福満 隼人, 坂東 弘教, 山本 雅昭, 廣田 勇士, 田中 敬子, 森貞 直哉, 長坂 美和子, 福満 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 552 - 552, 日本語


• 局在診断に難渋するACTH依存性Cushing症候群の1例

  大町 侑香, 山本 雅昭, 坂東 弘教, 蟹江 慶太郎, 藤井 研己, 廣田 勇士, 井下 尚子, 石田 敦士, 山田 正三, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 567 - 567, 日本語


• セレン欠乏症により,肝障害と甲状腺機能異常を来した一例

  永野 浩平, 本村 悠馬, 蟹江 慶太郎, 坂東 弘教, 山田 倫子, 高橋 路子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 575 - 575, 日本語


• 嚢胞形成を伴う褐色細胞腫4例の嚢胞内カテコラミン分画の検討

  影山 智子, 坂東 弘教, 山本 雅昭, 蟹江 慶太郎, 神澤 真紀, 辻本 泰貴, 花山 亜沙, 芳野 啓, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 598 - 598, 日本語


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 605 - 605, 日本語


• 骨粗鬆症を契機に診断に至ったLoeys-Dietz症候群の一例

  辻本 泰貴, 山本 直希, 福満 隼人, 坂東 弘教, 山本 雅昭, 廣田 勇士, 田中 敬子, 森貞 直哉, 長坂 美和子, 福満 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 552 - 552, 日本語


• 局在診断に難渋するACTH依存性Cushing症候群の1例

  大町 侑香, 山本 雅昭, 坂東 弘教, 蟹江 慶太郎, 藤井 研己, 廣田 勇士, 井下 尚子, 石田 敦士, 山田 正三, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 567 - 567, 日本語


• セレン欠乏症により,肝障害と甲状腺機能異常を来した一例

  永野 浩平, 本村 悠馬, 蟹江 慶太郎, 坂東 弘教, 山田 倫子, 高橋 路子, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 575 - 575, 日本語


• 嚢胞形成を伴う褐色細胞腫4例の嚢胞内カテコラミン分画の検討

  影山 智子, 坂東 弘教, 山本 雅昭, 蟹江 慶太郎, 神澤 真紀, 辻本 泰貴, 花山 亜沙, 芳野 啓, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 598 - 598, 日本語


• Cushing症候群患者が認識する特異的症候と医師の診断との乖離

  本村 悠馬, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年10月, 日本内分泌学会雑誌, 98(2) (2), 605 - 605, 日本語


• Corticotroph adenomaにおける腫瘍浸潤Tリンパ球とコルチゾールの関連

  神澤 真紀, 福岡 秀規, 蟹江 慶太郎, 志智 大成, 坂東 弘教, 山本 雅昭, 山田 正三, 小川 渉, 伊藤 智雄

  (一社)日本内分泌学会, 2022年08月, 日本内分泌学会雑誌, 98(Suppl.HPT) (Suppl.HPT), 34 - 37, 日本語


• 肺炎治療中に急激に発症し短期間で改善したSLE併発B型インスリン抵抗症の1例

  三輪 一貴, 西影 星二, 山下 真依, 白杉 郁, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 三枝 淳, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年05月, 糖尿病, 65(5) (5), 256 - 256, 日本語


• ニボルマブの初回投与から1988日後に劇症1型糖尿病様の糖尿病を発症した1例

  本村 悠馬, 佐々木 百合子, 上田 真莉子, 浦井 伸, 蟹江 慶太郎, 芳野 啓, 山本 雅昭, 坂東 弘教, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年05月, 糖尿病, 65(5) (5), 250 - 250, 日本語


• インスリン抗体の性質変化に伴いインスリン注射回数の変更を要した1型糖尿病の1例

  宮崎 裕也, 辻本 泰貴, 大井 佑夏, 芳野 啓, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年05月, 糖尿病, 65(5) (5), 252 - 252, 日本語


• 術前の血清コルチゾール濃度は高度肥満男性における腹腔鏡下スリーブ状胃切除術後の減量効果を予測する因子である

  田守 義和, 北浜 誠一, 坂東 弘教, 三浦 洋, 木村 真希, 中島 進介, 高橋 哲也, 坂口 一彦, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 148, 日本語


• 免疫チェックポイント阻害薬投与後に発症した1型糖尿病様の糖尿病の特徴と膵臓MRI所見との関連についての検討

  前田 岳志, 芳野 啓, 西山 信晴, 本村 悠馬, 鈴木 正暉, 井上 朋也, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, 日本語


• SGLT2阻害薬投与後のHb増加に伴うGA/HbA1c比への影響に関する検討

  芳野 啓, 本村 悠馬, 西影 星二, 山本 あかね, 坂東 弘教, 山本 雅昭, 福岡 秀規, 芳野 弘, 芳野 原, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 177, 日本語


• 肥満症における11の健康障害と長期的な体重変化との関連の検討

  影山 智子, 西影 星二, 村前 直和, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 199, 日本語


• 肥満症患者における食行動質問表の各因子スコアと減量効果予測の検討

  友藤 清爾, 西影 星二, 村前 直和, 芳野 啓, 坂東 弘教, 山本 雅昭, 福岡 秀規, 高橋 路子, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, 日本語


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋 路子, 山田 倫子, 村前 直和, 尾上 弘美, 鍛冶 亜由美, 三ヶ尻 礼子, 山本 育子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 田守 義和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, 日本語


• ダンピング症候群による低血糖のため診断に難渋したインスリノーマの一例

  藤井 研己, 蟹江 慶太郎, 山本 雅昭, 坂東 弘教, 廣田 勇士, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2022年04月, 日本内分泌学会雑誌, 98(1) (1), 370 - 370, 日本語


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本 直希, 浦井 伸, 鈴木 正暉, 佐々木 百合子, 大井 佑夏, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 160, 日本語


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井 佑夏, 山本 雅昭, 佐々木 百合子, 鈴木 正暉, 山本 直希, 浦井 伸, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 高橋 路子, 井口 元三, 高橋 裕, 福岡 秀規, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 161, 日本語


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木 正暉, 浦井 伸, 福岡 秀規, 廣田 勇士, 山本 直希, 志智 大城, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 169, 日本語


• 1型糖尿病患者におけるSGLT2阻害薬使用の影響に関する検討

  本村 悠馬, 芳野 啓, 山本 あかね, 上田 真莉子, 松岡 敦子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 177, 日本語


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋 路子, 山田 倫子, 村前 直和, 尾上 弘美, 鍛冶 亜由美, 三ヶ尻 礼子, 山本 育子, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 田守 義和, 廣田 勇士, 小川 渉

  (一社)日本糖尿病学会, 2022年04月, 糖尿病, 65(Suppl.1) (Suppl.1), S - 308, 日本語


• 肥満のゲノムサイエンス 減量外来受診後にパイロシークエンス法によって診断し得たPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 山田 倫子, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本肥満学会, 2022年03月, 肥満研究, 27(Suppl.) (Suppl.), 176 - 176, 日本語


• 肥満のゲノムサイエンス 減量外来受診後にパイロシークエンス法によって診断し得たPrader-Willi症候群の一例

  高橋 路子, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三, 山田 倫子, 森貞 直哉, 松原 圭子, 鏡 雅代, 緒方 勤, 高橋 裕, 小川 渉

  (一社)日本肥満学会, 2022年03月, 肥満研究, 27(Suppl.) (Suppl.), 176 - 176, 日本語


• Gonadotroph tumorとsomatotroph tumorのcollisionと考えられた一例

  神澤真紀, 辻本泰貴, 山本雅昭, 蟹江慶太郎, 坂東弘教, 坂東弘教, 中井友昭, 篠山隆司, 井下尚子, 福岡秀規, 小川渉, 伊藤智雄

  2022年, 日本臨床内分泌病理学会学術総会プログラム・抄録集, 26th


• 先端巨大症患者におけるBMIと肥満関連疾患の有病率についての検討

  山本直希, 浦井伸, 鈴木正暉, 佐々木百合子, 大井佑夏, 志智大城, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 1型糖尿病(T1DM)患者におけるIGF-Iと自由行動下のCGM指標に関連する因子の検討

  鈴木正暉, 浦井伸, 福岡秀規, 廣田勇士, 山本直希, 志智大城, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症患者における食行動質問表の各因子スコアと減量効果予測の検討

  友藤清爾, 西影星二, 村前直和, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 高橋路子, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• Free StyleリブレLink使用者の背景および導入前後におけるスキャン回数,HbA1cの変化の検討

  芳野啓, 花山亜沙, 上田真莉子, 松岡敦子, 山本あかね, 蟹江慶太郎, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症における11の健康障害と長期的な体重変化との関連の検討

  影山智子, 西影星二, 村前直和, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 高橋路子, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• SGLT2阻害薬投与後のHb増加に伴うGA/HbA1c比への影響に関する検討

  芳野啓, 本村悠馬, 西影星二, 西影星二, 山本あかね, 坂東弘教, 山本雅昭, 福岡秀規, 芳野弘, 芳野原, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• インスリン抗体の性質変化に伴いインスリン注射回数の変更を要した1型糖尿病の1例

  宮崎裕也, 辻本泰貴, 大井佑夏, 芳野啓, 坂東弘教, 蟹江慶太郎, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(5) (5)


• 成人成長ホルモン分泌不全症(AGHD)患者におけるGH補充療法による耐糖能への影響に関する検討

  大井佑夏, 山本雅昭, 佐々木百合子, 鈴木正暉, 山本直希, 浦井伸, 志智大城, 蟹江慶太郎, 坂東弘教, 高橋路子, 高橋路子, 井口元三, 井口元三, 高橋裕, 福岡秀規, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 肺炎治療中に急激に発症し短期間で改善したSLE併発B型インスリン抵抗症の1例

  三輪一貴, 西影星二, 山下真依, 白杉郁, 芳野啓, 坂東弘教, 山本雅昭, 福岡秀規, 三枝淳, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(5) (5)


• 免疫チェックポイント阻害薬投与後に発症した1型糖尿病様の糖尿病の特徴と膵臓MRI所見との関連についての検討

  前田岳志, 芳野啓, 西山信晴, 本村悠馬, 鈴木正暉, 井上朋也, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 肥満症患者に対する術前減量サポートの効果と周術期合併症に関する検討

  高橋路子, 高橋路子, 山田倫子, 山田倫子, 村前直和, 尾上弘美, 鍛冶亜由美, 三ヶ尻礼子, 山本育子, 坂東弘教, 山本雅昭, 福岡秀規, 井口元三, 井口元三, 田守義和, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 1型糖尿病患者におけるSGLT2阻害薬使用の影響に関する検討

  本村悠馬, 芳野啓, 山本あかね, 上田真莉子, 松岡敦子, 蟹江慶太郎, 坂東弘教, 坂東弘教, 山本雅昭, 福岡秀規, 廣田勇士, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• 若年で糖尿病を発症した小児がん経験者の1例

  佐々木百合子, 坂東弘教, 藤井研己, 西影星二, 山本雅昭, 芳野啓, 蟹江慶太郎, 廣田勇士, 福岡秀規, 小川渉

  2022年, 糖尿病(Web), 65(Suppl) (Suppl)


• Cushing症候群診断時における自覚症状と他覚所見の乖離について

  本村悠馬, 浦井伸, 坂東弘教, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022年, 日本内分泌学会雑誌, 98(1) (1)


• 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデルの樹立

  蟹江慶太郎, 伊藤剛, 井口元三, 松本隆作, 浦井伸, 坂東弘教, 山本雅昭, 福岡秀規, 小川渉, 金子新, 高橋裕

  2022年, 日本内分泌学会雑誌, 98(1) (1)


• 甲状腺刺激ホルモン(TSH)の測定系のハーモナイゼーションから探る測定系に不安定性を与える因子の検討

  生戸健一, 坂東弘教, 福岡秀規, 山本雅昭, 小笠原綾子, 佐藤伊都子, 今西孝充, 岡野隆一, 小川渉, 矢野嘉彦

  2022年, 日本内分泌学会雑誌, 98(1) (1)


• グルココルチコイド補充中患者におけるCOVID-19ワクチン接種後のステロイドカバーに関する実態調査

  友藤清爾, 坂東弘教, 山本雅昭, 高橋路子, 高橋路子, 佐々木百合子, 大井佑夏, 穂積かおり, 西影星二, 浦井伸, 志智大城, 山本直希, 鈴木正暉, 蟹江慶太郎, 井口元三, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022年, 日本内分泌学会雑誌, 98(1) (1)


• Cushing症候群診断時における自覚症状と他覚所見の乖離について

  本村悠馬, 浦井伸, 坂東弘教, 山本雅昭, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022年, 間脳・下垂体・副腎系研究会プログラム・抄録集(Web), 33rd


• 輸血によりゴナドトロピン単独欠損症をきたした再生不良性貧血の一例

  山本直希, 浦井伸, 山本雅昭, 坂東弘教, 坂東弘教, 鈴木正暉, 佐々木百合子, 大井佑夏, 志智大城, 蟹江慶太郎, 井口元三, 井口元三, 福岡秀規, 小川渉

  2022年, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• グルココルチコイド補充療法患者におけるCOVID-19ワクチン接種後のステロイドカバーに関する実態調査

  坂東弘教, 山本雅昭, 高橋路子, 高橋路子, 佐々木百合子, 大井佑夏, 穂積かおり, 西影星二, 浦井伸, 志智大城, 山本直希, 鈴木正暉, 蟹江慶太郎, 福岡秀規, 井口元三, 井口元三, 井口元三, 小川渉

  2022年, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 重症筋無力症を合併した抗PIT-1下垂体炎の新規症例

  浦井伸, 大井佑夏, 蟹江慶太郎, 山本雅昭, 坂東弘教, 坂東弘教, 山本直希, 鈴木正暉, 志智大城, 福岡秀規, 井口元三, 井口元三, 井口元三, 小川渉

  2022年, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 神戸大学医学部附属病院におけるクッシング病の診療実態

  福岡秀規, 山本雅昭, 坂東弘教, 蟹江慶太郎, 志智大城, 浦井伸, 山本直希, 鈴木正暉, 大井佑夏, 佐々木百合子, 高橋路子, 井口元三, 井口元三, 谷口理章, 西岡宏, 山田正三, 山田正三, 高橋裕, 高橋裕, 小川渉

  2022年, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• USP8変異はAVPR1b受容体高発現を介してクッシング病のDDAVP試験反応性と関連する

  志智大城, 福岡秀規, 神澤真紀, 山本直希, 鈴木正暉, 浦井伸, 蟹江慶太郎, 坂東弘教, 山本雅昭, 井口元三, 井下尚子, 山田正三, 高橋裕, 高橋裕, 小川渉

  2022年, 日本間脳下垂体腫瘍学会プログラム・抄録集, 32nd


• 重症筋無力症を合併した抗PIT-1下垂体炎の1例

  大井 佑夏, 浦井 伸, 山本 雅昭, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年12月, 日本内分泌学会雑誌, 97(4) (4), 907 - 907, 日本語


• 重症筋無力症を合併した抗PIT-1下垂体炎の1例

  大井 佑夏, 浦井 伸, 山本 雅昭, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年12月, 日本内分泌学会雑誌, 97(4) (4), 907 - 907, 日本語


• 胸腺腫術後に重症筋無力症を発症した抗PIT-1下垂体炎の1例

  大井 佑夏, 山本 雅昭, 浦井 伸, 坂東 弘教, 稲葉 惟子, 蟹江 慶太郎, 井口 元三, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 487 - 487, 日本語


• USP8変異はV1b受容体発現、DDAVP試験反応性亢進と関連する

  志智 大城, 福岡 秀規, 神澤 真紀, 山本 直希, 鈴木 正暉, 浦井 伸, 蟹江 慶太郎, 坂東 弘教, 山本 雅昭, 井口 元三, 山田 正三, 高橋 裕, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 501 - 501, 日本語


• 発症36年後に抗ラブフィリン3A抗体陽性を示した尿崩症の1例

  西影 星二, 山本 雅昭, 稲葉 惟子, 坂東 弘教, 芳野 啓, 廣田 勇士, 椙村 益久, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 505 - 505, 日本語


• COVID-19治療中の高血圧クリーゼから診断した褐色細胞腫の一例

  辻本 泰貴, 西影 星二, 山本 雅昭, 西坂 まり華, 芳野 啓, 蟹江 慶太郎, 廣田 勇士, 坂東 弘教, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 528 - 528, 日本語


• ICIとTKI使用後に原発性副腎不全を生じた腎癌の2例

  西坂 まり華, 坂東 弘教, 蟹江 慶太郎, 山本 雅昭, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 533 - 533, 日本語


• paragangliomaとganglioneuromaの混合腫瘍の1例

  佐々木 百合子, 山本 雅昭, 神澤 真紀, 蟹江 慶太郎, 重村 克巳, 神田 知紀, 上田 真莉子, 坂東 弘教, 芳野 啓, 廣田 勇士, 藤澤 正人, 福岡 秀規, 小川 渉

  (一社)日本内分泌学会, 2021年10月, 日本内分泌学会雑誌, 97(2) (2), 539 - 539, 日本語


• 【日常診療で内分泌疾患を見逃さない!】代表的内分泌疾患 下垂体疾患 プロラクチノーマ 月経異常を見逃さない!

  坂東 弘教, 福岡 秀規

  (株)医学書院, 2021年08月, Medicina, 58(9) (9), 1355 - 1359, 日本語


• 内分泌研究のインパクト 自己免疫性下垂体疾患の新たな病態の解明と革新的アプローチ

  高橋 裕, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, 2021年04月, 日本内分泌学会雑誌, 97(1) (1), 122 - 122, 日本語


• 下垂体の疾患へのアプローチ 下垂体疾患の病態解明を目指したiPS細胞の応用

  高橋 裕, 松本 隆作, 蟹江 慶太郎, 浦井 伸, 坂東 弘教, 山本 雅昭, 井口 元三, 福岡 秀規

  (一社)日本内分泌学会, 2021年04月, 日本内分泌学会雑誌, 97(1) (1), 167 - 167, 日本語


• 両側副腎での¹²³I-MIBG陽性例における臨床的,病理学的検討

  稲葉惟子, 山本雅昭, 神澤真紀, 青山弥生, 神田知紀, 中村保宏, 坂東弘教, 福岡秀規, 小川渉

  2021年, 日本臨床内分泌病理学会学術総会プログラム・抄録集, 25th


• 疾患iPS細胞を用いた自己免疫性下垂体疾患のin vitro疾患モデルの樹立

  蟹江慶太郎, 伊藤剛, 井口元三, 坂東弘教, 山本雅昭, 福岡秀規, 金子新, 高橋裕

  2021年, 日本神経内分泌学会学術集会プログラム・抄録集, 47th


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 坂東 弘教, 六車 恵子, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  日本臨床分子医学会, 2020年04月, 日本臨床分子医学会学術総会プログラム・抄録集, 57回, 78 - 78, 日本語

  [査読有り]


• 疾患iPS細胞/抗原特異的T細胞を用いた抗PIT-1下垂体炎疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 伊藤 剛, 喜多山 秀一, 坂東 弘教, 六車 恵子, 松本 隆作, 山本 雅昭, 福岡 秀規, 金子 新, 小川 渉, 高橋 裕

  日本臨床分子医学会, 2020年04月, 日本臨床分子医学会学術総会プログラム・抄録集, 57回(1) (1), 78 - 78, 日本語


• SAT-042 Pituitary Expression Of Isl1 Prevents Ectopic, Foxa1 And Foxj1 Mediated Differentiation Of Progenitors Into Rathke’S Cleft Cysts.

  Camper S, Brinkmeier M, Bando H, Fujio S, Yashimoto K, Camarano A, de Souza F

  2019年04月, Journal of the Endocrine Society


• SAT-LB079 Clinical Heterogeneity of Acquired Idiopathic ACTH Deficiency: A New Classification Based on the Clinical Characteristics and Autoantibodies.

  FUJITA Y, Bando H, Iguchi G, Iida K, Shichi H, Kanie K, Matsumoto R, Suda K, Fukuoka H, Ogawa W, Takahashi Y

  2019年04月, Journal of the Endocrine Society


• OR24-1 Structure-Function Analysis of Human OTX2 Variants Defines Required Region of C-Terminus for Pituitary, Eye, and Craniofacial Development.

  Bando H, Carvalho L, Bohnsack B, Moreira M, Antonellis A, Arnhold I, Camper S, Gergics P

  2019年04月, Journal of the Endocrine Society


• MON-435 The Responsiveness To Ddavp Test Predicts Usp8 Mutation In Patients With Cushing's Disease.

  Shichi H, Fukuoka H, Matsumoto R, Kanie K, Fujita Y, Iguchi G, Suda K, Bando H, Inoshita N, Yamada S, Ogawa W, Takahashi Y

  2019年04月, Journal of the Endocrine Society


• 疾患iPS細胞を用いた抗PIT-1抗体症候群疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 松本 隆作, 六車 恵子, 志智 大城, 藤田 泰功, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2019年04月, 日本内分泌学会雑誌, 95(1) (1), 390 - 390, 日本語


• ACTH単独欠損症において抗コルチコトロフ抗体の存在は重症度と関連する

  藤田 泰功, 坂東 弘教, 井口 元三, 飯田 啓二, 志智 大城, 蟹江 慶太郎, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2019年04月, 日本内分泌学会雑誌, 95(1) (1), 430 - 430, 日本語


• 疾患iPS細胞を用いた抗PIT-1抗体症候群疾患モデルの樹立

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 松本 隆作, 六車 恵子, 志智 大城, 藤田 泰功, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2019年04月, 日本内分泌学会雑誌, 95(1) (1), 390 - 390, 日本語


• ACTH単独欠損症において抗コルチコトロフ抗体の存在は重症度と関連する

  藤田 泰功, 坂東 弘教, 井口 元三, 飯田 啓二, 志智 大城, 蟹江 慶太郎, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2019年04月, 日本内分泌学会雑誌, 95(1) (1), 430 - 430, 日本語


• ARMC5変異を認めたPBMAHと異所性副甲状腺腫によるPHPTの合併例

  苛原 彩, 福岡 秀規, 吉田 健一, 土橋 一生, 坂東 弘教, 岡田 裕子, 井口 元三, 小川 裕行, 神澤 真紀, 坂井 誠, 臼井 健, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 713 - 713, 日本語


• 本邦におけるPMAHの遺伝的背景とその臨床的特徴

  姜 知佳, 小杉 理英子, 臼井 健, 鳥居 みずき, 米本 崇子, 小川 達雄, 田村 尚久, 金本 巨哲, 村部 浩之, 菱田 吉明, 方波見 卓行, 坂東 弘教, 福岡 秀規, 井上 達秀

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 712 - 712, 日本語


• Cushing病におけるDDAVP試験の反応性とその臨床的特徴の検討

  志智 大城, 福岡 秀規, 松本 隆作, 蟹江 慶太郎, 藤田 泰功, 井口 元三, 隅田 健太郎, 坂東 弘教, 井下 尚子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 607 - 607, 日本語


• 免疫チェックポイント阻害薬関連下垂体炎における自己抗体の同定

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 志智 大城, 藤田 泰功, 小武 由紀子, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 607 - 607, 日本語


• 診断に難渋したTSH単独分泌不全症の一例

  隅田 健太郎, 千原 和夫, 志智 大城, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 坂東 弘教, 高橋 路子, 福岡 秀規, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 681 - 681, 日本語


• 非機能性副腎腫瘍の不均一性から見る機能性腫瘍診断基準の問題点

  松本 隆作, 山田 倫子, 福岡 秀規, 井口 元三, 藤田 奏功, 蟹江 慶太郎, 坂東 弘教, 隅田 健太郎, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年09月, 日本内分泌学会雑誌, 94(2) (2), 714 - 714, 日本語


• 鞍上部海綿状血管腫術後に高度肥満を含む視床下部症候群を呈し治療に難渋した一例

  藤田 泰功, 金谷 雅之, 浦井 伸, 蟹江 慶太郎, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 岡田 裕子, 福岡 秀規, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本肥満学会, 2018年09月, 肥満研究, 24(Suppl.) (Suppl.), 194 - 194, 日本語


• 2型糖尿病患者の血中IGF-I値に影響を与える因子の検討

  隅田 健太郎, 福岡 秀規, 廣田 勇士, 坂東 弘教, 高橋 路子, 井口 元三, 木南 佐織, 坂口 一彦, 千原 和夫, 小川 渉, 高橋 裕

  (一社)日本糖尿病学会, 2018年06月, 糖尿病, 61(6) (6), 401 - 401, 日本語


• 自己免疫性溶血性貧血と偽性副甲状腺機能低下症を合併した一例

  坂本 洋一, 福岡 秀規, 野崎 高史, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年06月, 日本内分泌学会雑誌, 94(Suppl.Update) (Suppl.Update), 32 - 34, 日本語


• Luscan-Lumish症候群による巨人症の機序の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 坂東 弘教, 高橋 路子, 千原 和夫, 鳴海 覚志, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 277 - 277, 日本語


• 自己免疫性下垂体疾患 新たな自己免疫性下垂体疾患 抗PIT-1抗体症候群の病態

  井口 元三, 坂東 弘教, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 186 - 186, 日本語


• ACTH産生下垂体腺腫の浸潤性に関連するLong noncoding RNA、CRNDEの同定

  吉田 健一, 福岡 秀規, 藤田 泰功, 蟹江 慶一郎, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 高橋 路子, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 313 - 313, 日本語


• ACTH単独欠損症の新たな成因 腫瘍随伴症候群

  坂東 弘教, 井口 元三, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 341 - 341, 日本語


• 特発性中枢性尿崩症とPRL単独欠損症を合併した1例

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 藤原 えり, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 342 - 342, 日本語


• 発症前からの経時的な内分泌学的評価が可能であったニボルマブ関連下垂体炎の一例

  藤田 泰功, 福岡 秀規, 中野 温子, 友藤 清爾, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2018年04月, 日本内分泌学会雑誌, 94(1) (1), 386 - 386, 日本語


• 下垂体-副腎の分子生物学 Long noncoding RNA、CRNDEはACTH産生下垂体腺腫の増殖、浸潤性に関連する

  福岡 秀規, 吉田 健一, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 藤田 泰功, 蟹江 慶太郎, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  間脳・下垂体・副腎系研究会, 2018年03月, ACTH RELATED PEPTIDES, 29, 42 - 43, 日本語


• Luscan-Lumish症候群による巨人症の機序の解析

  隅田健太郎, 福岡秀規, 井口元三, 蟹江慶太郎, 藤田泰功, 小武由紀子, 吉田健一, 坂東弘教, 高橋路子, 千原和夫, 鳴海覚志, 小川渉, 長谷川奉延, 高橋裕

  2018年, 日本内分泌学会雑誌, 94(1) (1)


• 遺伝性平滑筋腫症・腎細胞癌症候群に合併した副腎腫瘍の意義

  隅田 健太郎, 福岡 秀規, 小野 克彦, 重村 克巳, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 坂東 弘教, 高橋 路子, 井口 元三, 木南 佐織, 千原 和夫, 藤澤 正人, 山崎 有人, 笹野 公伸, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 535 - 535, 日本語


• 自己免疫性溶血性貧血と偽性副甲状腺機能低下症を合併した一例

  坂本 洋一, 福岡 秀規, 野崎 高史, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 568 - 568, 日本語


• パシレオチドLARが奏功した先端巨大症の2例

  藤原 えり, 福岡 秀規, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 546 - 546, 日本語


• big ACTH分泌を認めたサブクリニカルクッシング病の一例

  小武 由紀子, 福岡 秀規, 金谷 雅之, 佐藤 伊都子, 蟹江 慶太郎, 藤田 泰功, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 550 - 550, 日本語


• 肺大細胞神経内分泌癌を合併したACTH単独欠損症の一例

  坂東 弘教, 井口 元三, 蟹江 慶太郎, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 550 - 550, 日本語


• 当院で経験した免疫チェックポイント阻害薬関連下垂体炎の4例

  蟹江 慶太郎, 井口 元三, 坂東 弘教, 立花 真理子, 金谷 雅之, 山田 倫子, 藤田 泰功, 小武 由紀子, 吉田 健一, 松本 隆作, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 552 - 552, 日本語


• 先端巨大症におけるHPA軸の検討

  小原 靖子, 福岡 秀規, 中山 真理子, 藤田 泰功, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 596 - 596, 日本語


• 日本人Cushing症候群におけるCushingQoLの応用

  藤田 泰功, 福岡 秀規, 瀬尾 あかね, 中野 温子, 蟹江 慶太郎, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 岡田 裕子, 井口 元三, Webb Susan, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年10月, 日本内分泌学会雑誌, 93(2) (2), 599 - 599, 日本語


• Luscan-Lumish症候群による巨人症の機序の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 鳴海 覚志, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 263 - 263, 日本語


• IgG4関連疾患の基礎と臨床 IgG4関連下垂体炎の病態、診断と治療

  井口 元三, 坂東 弘教, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 176 - 176, 日本語


• 下垂体自己免疫の新たな病態

  井口 元三, 坂東 弘教, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 225 - 225, 日本語


• 下垂体自己免疫の新たな病態 症例提示

  坂東 弘教, 井口 元三, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 227 - 227, 日本語


• 抗PIT-1抗体症候群の発症機序の解明

  坂東 弘教, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 隈田 健太郎, 西澤 衡, 福岡 秀規, 犬塚 恵, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 249 - 249, 日本語


• 疾患特異的iPS細胞を用いた先天性下垂体機能低下症の病態解明

  松本 隆作, 須賀 英隆, 青井 貴之, 坂東 弘教, 福岡 秀規, 井口 元三, 鳴海 覚志, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 249 - 249, 日本語


• 成長ホルモン分泌不全症における肝線維化を予測する非侵襲的マーカーの検討

  西澤 衡, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 264 - 264, 日本語


• Cushing症候群薬物療法中患者のバイオマーカーとしての唾液コルチゾールの有用性の検討

  吉田 健一, 福岡 秀規, 山田 倫子, 中島 進介, 立花 真莉子, 細川 友誠, 岩橋 泰幸, 伊藤 潤, 三浦 洋, 末松 那都, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 廣田 勇士, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 267 - 267, 日本語


• 緩徐1型糖尿病、バセドウ病を合併した偽性偽性副甲状腺機能低下症の一例

  小武 由紀子, 福岡 秀規, 平田 悠, 高橋 陸, 毛利 華奈子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 岡田 裕子, 廣田 勇士, 高橋 路子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年04月, 日本内分泌学会雑誌, 93(1) (1), 370 - 370, 日本語


• 胸腺腫に関連した新規疾患概念、抗PIT-1抗体症候群

  松本 高典, 小川 裕行, 酒井 秀都, 金 泰雄, 内田 孝宏, 木村 賢司, 清水 奈保子, 田中 雄悟, 坂東 弘教, 井口 元三, 高橋 裕, 眞庭 謙昌

  (NPO)日本呼吸器外科学会, 2017年04月, 日本呼吸器外科学会雑誌, 31(3) (3), O14 - 6, 日本語


• 遺伝性平滑筋腫症・腎細胞癌症候群に合併した副腎腫瘍の意義

  隅田健太郎, 隅田健太郎, 福岡秀規, 小野克彦, 重村克巳, 蟹江慶太郎, 藤田泰功, 小武由紀子, 吉田健一, 坂東弘教, 高橋路子, 井口元三, 木南佐織, 千原和夫, 藤澤正人, 山崎有人, 笹野公伸, 小川渉, 高橋裕

  2017年, 日本内分泌学会雑誌, 93(2) (2)


• 特発性後天性全身性無汗症に中枢性尿崩症を合併した一例

  小畠 正樹, 福岡 秀規, 坂東 弘教, 高橋 陸, 山田 倫子, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2017年01月, 日本内分泌学会雑誌, 92(3) (3), 732 - 732, 日本語


• 特発性後天性全身性無汗症に中枢性尿崩症を合併した一例

  高橋 隆, 福岡 秀規, 坂東 弘教, 山田 倫子, 岡田 裕子, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 453 - 453, 日本語


• NF1に先端巨大症を含む多発性内分泌腫瘍を合併した一例

  小武 由紀子, 福岡 秀規, 穂積 かおり, 竹内 健人, 佐藤 武志, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 長谷川 奉延, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 460 - 460, 日本語


• 下垂体機能低下症を呈する「抗PIT-1抗体症候群」4例の臨床的検討

  坂東 弘教, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 福岡 秀規, 犬塚 恵, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 495 - 495, 日本語


• 健常人における血中IGF-I濃度を規定する因子の検討

  松本 隆作, 古賀 正史, 笠山 宗正, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 501 - 501, 日本語


• リチウム製剤により腎性尿崩症・副甲状腺機能亢進症を呈した1例

  吉田 健一, 福岡 秀規, 山田 佳子, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 廣田 勇士, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 516 - 516, 日本語


• 2型糖尿病患者におけるIGF-I低値に寄与する因子の解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年10月, 日本内分泌学会雑誌, 92(2) (2), 528 - 528, 日本語


• 新たな下垂体炎、視床下部自己抗体疾患 下垂体機能低下症を呈する新たな疾患概念「抗PIT-1抗体症候群」

  高橋 裕, 坂東 弘教, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 140 - 140, 日本語


• 抗PIT-1抗体症候群は新たな胸腺腫関連自己免疫疾患である

  坂東 弘教, 井口 元三, 福岡 秀規, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西沢 衡, 高橋 路子, 杢保 敦子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 202 - 202, 日本語


• IGF-Iの細胞老化促進作用を介した新たな肝臓調節機構と治療応用

  西沢 衡, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 219 - 219, 日本語


• ACTH産生下垂体腫瘍の新たな発症機序 Cyclin EはHOTAIRを負に制御する

  吉田 健一, 福岡 秀規, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 231 - 231, 日本語


• ACTH産生下垂体腫瘍におけるErbB4の発現量と臨床像との関連

  小武 由紀子, 福岡 秀規, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 井口 元三, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 260 - 260, 日本語


• 疾患特異的iPS細胞を用いた下垂体疾患の病態解明

  松本 隆作, 須賀 英隆, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高木 優樹, 石井 智弘, 長谷川 奉延, 六車 恵子, 青井 貴之, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 300 - 300, 日本語


• ヒストンメチル基転移酵素SETD2遺伝子変異を認めた巨人症の一例

  隅田 健太郎, 鳴海 覚志, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西沢 衡, 高橋 路子, 小川 渉, 長谷川 奉延, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 301 - 301, 日本語


• 新規アディポカイン、ケマリンは副腎髄質を介して褐色脂肪機能を調節する

  高橋 路子, 置村 康彦, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 福岡 秀規, 井口 元三, 北澤 理子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 309 - 309, 日本語


• 原発性アルドステロン症69例における片側性あるいは両側性病変の臨床的特徴の検討

  井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 福岡 秀規, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2016年04月, 日本内分泌学会雑誌, 92(1) (1), 319 - 319, 日本語


• 糖尿病合併先端巨大症における糖尿病性血管合併症の頻度

  隈田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本糖尿病学会, 2016年04月, 糖尿病, 59(Suppl.1) (Suppl.1), S - 154, 日本語


• 本邦先端巨大症における包括的原因遺伝子解析

  松本 隆作, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 797 - 797, 日本語


• 先端巨大症における膵嚢胞性病変の合併頻度とその関連因子の検討

  小武 由紀子, 福岡 秀規, 有坂 好史, 小西 淳也, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西沢 衡, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 799 - 799, 日本語


• 糖尿病合併先端巨大症における糖尿病性血管合併症の頻度

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 800 - 800, 日本語


• 治療に苦慮したTR-Ab著明高値バセドウ病合併妊娠の1例

  吉田 健一, 福岡 秀規, 深田 修司, 小武 由紀子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 井口 元三, 豊永 綾香, 上中 美月, 西田 浩輔, 森岡 一朗, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 810 - 810, 日本語


• トルバブタンが著効した低AVP血症性低ナトリウム血症の一例

  坂東 弘教, 井口 元三, 福岡 秀規, 小武 由紀子, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 856 - 856, 日本語


• 集学的治療によって長期生存している悪性褐色細胞腫の一例

  西澤 衡, 福岡 秀規, 井口 元三, 小武 由紀子, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 向原 徹, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年10月, 日本内分泌学会雑誌, 91(3) (3), 861 - 861, 日本語


• 脳と下垂体の臨床update 病態・診断・治療 下垂体機能低下症を呈する新たな疾患概念

  高橋 裕, 坂東 弘教, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, 2015年09月, 日本内分泌学会雑誌, 91(2) (2), 502 - 502, 日本語


• IGF-Iはテロメア短縮および細胞老化を惹起する 先端巨大症における新たな病態の提唱

  松本 隆作, 福岡 秀規, 井口 元三, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年04月, 日本内分泌学会雑誌, 91(1) (1), 266 - 266, 日本語


• 2型糖尿病における細小および大血管合併症と血中IGF-I値の関連

  隅田 健太郎, 福岡 秀規, 井口 元三, 廣田 勇士, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年04月, 日本内分泌学会雑誌, 91(1) (1), 270 - 270, 日本語


• 免疫染色により責任病巣を評価しえたPA/SCS合併の1症例

  西澤 衡, 福岡 秀規, 生天目 侑子, 廣田 勇士, 井口 元三, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 坂口 一彦, 笹野 公伸, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年04月, 日本内分泌学会雑誌, 91(1) (1), 365 - 365, 日本語


• 新規胸腺腫関連自己免疫疾患としての"抗PIT-1抗体症候群"

  坂東 弘教, 井口 元三, 福岡 秀規, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 東條 克能, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年04月, 日本内分泌学会雑誌, 91(1) (1), 382 - 382, 日本語


• Cushing症候群患者におけるメチラポン治療効果指標としての唾液中コルチゾールの有用性

  吉田 健一, 福岡 秀規, 中島 進介, 岩橋 泰幸, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 井口 元三, 廣田 勇士, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2015年04月, 日本内分泌学会雑誌, 91(1) (1), 397 - 397, 日本語


• 先端巨大症においては末梢血テロメア長が短縮している

  松本 隆作, 福岡 秀規, 井口 元三, 吉田 健一, 坂東 弘教, 隅田 健太郎, 西沢 衡, 高橋 路子, 山田 正三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2014年10月, 日本内分泌学会雑誌, 90(3) (3), 912 - 912, 日本語


• 日本人先端巨大症患者におけるAcroQoL日本語版の信頼性と有用性

  吉田 健一, 福岡 秀規, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 井口 元三, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2014年10月, 日本内分泌学会雑誌, 90(3) (3), 917 - 917, 日本語


• IgG4関連下垂体炎との鑑別を要した多発性血管炎性肉芽腫症の一例

  坂東 弘教, 井口 元三, 福岡 秀規, 齋藤 幹, 河野 誠司, 吉田 健一, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 谷口 理章, 森信 暁雄, 甲村 英二, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2014年10月, 日本内分泌学会雑誌, 90(3) (3), 922 - 922, 日本語


• 術後に心機能が改善したサブクリニカルクッシング症候群の1例

  隅田 健太郎, 井口 元三, 福岡 秀規, 廣田 勇士, 吉田 健一, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2014年10月, 日本内分泌学会雑誌, 90(3) (3), 931 - 931, 日本語


• 補充療法で多血症が改善した21水酸化酵素欠損症の一男性例

  西澤 衡, 福岡 秀規, 井口 元三, 吉田 健一, 松本 隆作, 坂東 弘教, 隅田 健太郎, 豊田 有子, 本間 桂子, 長谷川 泰延, 臼井 健, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2014年10月, 日本内分泌学会雑誌, 90(3) (3), 968 - 968, 日本語


• The Effect of Type 2 Diabetes on Serum GH and IGF-I Levels in Relatively Lean Japanese Patients

  Kentaro Suda, Ryusaku Matsumoto, Hidenori Fukuoka, Genzo Iguchi, Yushi Hirota, Hironori Bando, Hitoshi Nishizawa, Michiko Takahashi, Kazuhiko Sakaguchi, Yutaka Takahashi

  2014年06月, ENDOCRINE REVIEWS, 35(3) (3), 英語

  研究発表ペーパー・要旨（国際会議）


• 下垂体と自己免疫 多腺性自己免疫症候群に伴う下垂体炎と抗PIT-1抗体症候群のトピックス

  高橋 裕, 坂東 弘教, 山本 雅昭, 福岡 秀規, 井口 元三

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 211 - 211, 日本語


• 抗PIT-1抗体症候群においてはPIT-1に対する細胞障害性T細胞が存在する

  坂東 弘教, 井口 元三, 福岡 秀規, 山本 雅昭, 竹野 亮子, 松本 隆作, 隅田 健太郎, 西澤 衡, 高橋 路子, 東條 克能, 高橋 裕

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 257 - 257, 日本語


• ACTH産生下垂体腫瘍におけるカネルチニブのPOMC発現抑制効果とEGF受容体ファミリー発現量との関連

  福岡 秀規, 井口 元三, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 高橋 路子, 井下 尚子, 山田 正三, 高橋 裕

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 264 - 264, 日本語


• GHシグナルの亢進を認めたGH産生下垂体腺腫によらない巨人症の一例

  隅田 健太郎, 福岡 秀規, 井口 元三, 松本 隆作, 坂東 弘教, 西澤 衡, 高橋 路子, 高橋 裕

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 277 - 277, 日本語


• IGF-Iの新たな作用 星細胞の細胞老化を介した肝線維化抑制作用

  西澤 衡, 井口 元三, 松本 隆作, 坂東 弘教, 隅田 健太郎, 高橋 路子, 福岡 秀規, 高橋 裕

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 289 - 289, 日本語


• デスモプレシン経鼻から経口製剤への外来での切り替えについての検討

  松本 隆作, 福岡 秀規, 井口 元三, 坂東 弘教, 隅田 健太郎, 西澤 衡, 高橋 路子, 高橋 裕

  (一社)日本内分泌学会, 2014年04月, 日本内分泌学会雑誌, 90(1) (1), 293 - 293, 日本語


• 栄養介入・ステロイド補充にて全身状態が著明に改善した相対的副腎不全の一例

  高橋 路子, 永濱 郁代, 生田 智子, 堀川 真由美, 脇田 久美子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 福岡 秀規, 井口 元三, 戸田 明代, 濱田 康弘, 高橋 裕, 宇佐美 眞

  (一社)日本病態栄養学会, 2013年12月, 日本病態栄養学会誌, 17(Suppl.) (Suppl.), S - 106, 日本語


• 頭部外傷後に発症し失神発作をきたしたACTH単独欠損症の一例

  西澤 衡, 井口 元三, 松本 隆作, 坂東 弘教, 隅田 健太郎, 福岡 秀規, 廣田 勇士, 坂口 一彦, 小川 渉, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 933 - 933, 日本語


• 75gOGTTのGH高値は先端巨大症における大腸癌合併と関連している

  山本 雅昭, 福岡 秀規, 井口 元三, 高橋 路子, 西澤 衡, 隅田 健太郎, 坂東 弘教, 松本 隆作, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 937 - 937, 日本語


• 成人GH分泌不全症に対するGH補充療法 肝機能に関する長期成績

  松本 隆作, 福岡 秀規, 井口 元三, 西沢 衡, 坂東 弘教, 隅田 健太郎, 高橋 路子, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 974 - 974, 日本語


• 2型糖尿病による血中GH、IGF-I値への影響の検討

  隅田 健太郎, 松本 隆作, 福岡 秀規, 井口 元三, 廣田 勇士, 坂東 弘教, 西澤 衡, 高橋 路子, 坂口 一彦, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 975 - 975, 日本語


• 下垂体機能低下症、中枢性尿崩症におけるIgG4関連下垂体炎の頻度

  坂東 弘教, 井口 元三, 福岡 秀規, 隅田 健太郎, 松本 隆作, 西澤 衡, 高橋 路子, 谷口 理章, 甲村 英二, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 988 - 988, 日本語


• ステロイド補充が著効した重症患者における相対的副腎不全の一例

  高橋 路子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 福岡 秀規, 井口 元三, 宇佐美 眞, 高橋 裕

  (一社)日本内分泌学会, 2013年12月, 日本内分泌学会雑誌, 89(3) (3), 999 - 999, 日本語


• 栄養介入・ステロイド補充にて全身状態が著明に改善した相対的副腎不全の一例

  高橋 路子, 永濱 郁代, 生田 智子, 堀川 真由美, 脇田 久美子, 松本 隆作, 坂東 弘教, 隅田 健太郎, 西澤 衡, 福岡 秀規, 井口 元三, 戸田 明代, 濱田 康弘, 高橋 裕, 宇佐美 眞

  (一社)日本病態栄養学会, 2013年12月, 日本病態栄養学会誌, 17(Suppl.) (Suppl.), S - 106, 日本語


• SOCS2遺伝子変異により引き起こされた巨人症

  隅田 健太郎, 松本 隆作, 福岡 秀規, 井口 元三, 坂東 弘教, 西沢 衡, 高橋 路子, 高橋 裕

  (一社)日本内分泌学会, 2013年09月, 日本内分泌学会雑誌, 89(2) (2), 578 - 578, 日本語


• 2型糖尿病における先端巨大症の頻度についての検討

  隅田 健太郎, 井口 元三, 福岡 秀規, 廣田 勇士, 坂東 弘教, 山本 雅昭, 西沢 衡, 高橋 路子, 坂口 一彦, 高橋 裕

  (一社)日本内分泌学会, 2013年06月, 日本内分泌学会雑誌, 89(Suppl.Update) (Suppl.Update), 5 - 7, 日本語


• リンパ球性下垂体炎の合併が疑われた水疱性類天疱瘡の一例

  西澤 衡, 井口 元三, 坂東 弘教, 隅田 健太郎, 山本 雅昭, 高橋 路子, 福岡 秀規, 村西 浩二, 高橋 裕

  (一社)日本内分泌学会, 2013年06月, 日本内分泌学会雑誌, 89(Suppl.Update) (Suppl.Update), 30 - 32, 日本語


• IGF-IはNASHにおける線維化進展を防止する

  西澤 衡, 井口 元三, 坂東 弘教, 隅田 健太郎, 山本 雅昭, 高橋 路子, 福岡 秀規, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2013年04月, 日本内分泌学会雑誌, 89(1) (1), 240 - 240, 日本語


• 下垂体腫瘍を認めない巨人症におけるSOCS2、IGF-IRの遺伝子解析

  隅田 健太郎, 福岡 秀規, 井口 元三, 坂東 弘教, 山本 雅昭, 西澤 衡, 高橋 路子, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2013年04月, 日本内分泌学会雑誌, 89(1) (1), 254 - 254, 日本語


• 腎嚢胞は先端巨大症における脳動脈瘤合併の危険因子である

  山本 雅昭, 福岡 秀規, 井口 元三, 中島 進介, 高橋 路子, 西沢 衡, 隅田 健太郎, 坂東 弘教, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2013年04月, 日本内分泌学会雑誌, 89(1) (1), 320 - 320, 日本語


• IgG4陽性細胞が認められた肉芽腫性下垂体炎の1例

  坂東 弘教, 井口 元三, 福岡 秀規, 隅田 健太郎, 山本 雅昭, 西澤 衡, 高橋 路子, 谷口 理章, 甲村 英二, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2013年04月, 日本内分泌学会雑誌, 89(1) (1), 324 - 324, 日本語


• 巨大癰を併発した未治療2型糖尿病の1例

  池田 亜貴子, 陳 慶祥, 坂東 弘教, 船曳 あゆみ, 冨永 洋一, 西岡 美南, 川田 裕味子, 瀬戸 英伸

  (一社)日本糖尿病学会, 2013年02月, 糖尿病, 56(2) (2), 124 - 124, 日本語


• 2型糖尿病における先端巨大症の頻度についての検討

  隅田 健太郎, 井口 元三, 橋本 尚子, 廣田 勇士, 坂東 弘教, 山本 雅昭, 西澤 衡, 福岡 秀規, 高橋 路子, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2012年12月, 日本内分泌学会雑誌, 88(3) (3), 1013 - 1013, 日本語


• リンパ球性下垂体炎を合併したと考えられる水疱性類天疱瘡の一例

  西澤 衡, 中村 友昭, 井口 元三, 坂東 弘教, 隅田 健太郎, 山本 雅昭, 高橋 路子, 福岡 秀規, 橋本 尚子, 廣田 勇士, 坂口 一彦, 小川 渉, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2012年12月, 日本内分泌学会雑誌, 88(3) (3), 1014 - 1014, 日本語


• 妊娠、出産に成功した先端巨大症の1例

  高橋 路子, 福岡 秀規, 井口 元三, 西澤 衡, 山本 雅昭, 隅田 健太郎, 坂東 弘教, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2012年12月, 日本内分泌学会雑誌, 88(3) (3), 1047 - 1047, 日本語


• IgG4関連下垂体炎5例の臨床的検討

  坂東 弘教, 井口 元三, 福岡 秀規, 隅田 健太郎, 山本 雅昭, 西澤 衡, 高橋 路子, 清野 進, 高橋 裕

  (一社)日本内分泌学会, 2012年12月, 日本内分泌学会雑誌, 88(3) (3), 1050 - 1050, 日本語


• 抗PIT-1抗体症候群の病態と自己免疫性下垂体疾患における位置付け (特集 下垂体疾患最前線) -- (下垂体疾患の新しい病態)

  井口 元三, 坂東 弘教, 山本 雅昭

  医学の世界社, 2012年10月, ホルモンと臨床, 60(10) (10), 787 - 793, 日本語


• 下垂体と自己免疫 抗PIT-1抗体症候群 その後の展開

  高橋 裕, 坂東 弘教, 山本 雅昭, 井口 元三

  (一社)日本内分泌学会, 2012年09月, 日本内分泌学会雑誌, 88(2) (2), 604 - 604, 日本語


• 膵全摘・幽門側胃切後の膵性糖尿病に対し、CSIIを導入した1例

  武田 紗良, 坂東 弘教, 陳 慶祥, 船曳 あゆみ, 冨永 洋一

  (一社)日本糖尿病学会, 2012年08月, 糖尿病, 55(8) (8), 660 - 660, 日本語


• 感覚性失語にて横静脈洞血栓症を発症したコントロール不良の2型糖尿病の1例

  坂東 弘教, 大森 靖弘, 肥後 里実, 西岡 千晴, 名田 高幸, 冨永 洋一, 山田 浩幸, 北垣 一成

  (一社)日本糖尿病学会, 2012年08月, 糖尿病, 55(8) (8), 661 - 661, 日本語


• 1型糖尿病患者におけるカーボカウント法を継続できた群とできなかった群の患者および栄養士の要因背景

  備後 安輝子, 陳 慶祥, 岡本 泰幸, 西田 有里, 岡本 美紀, 寒川 美穂, 小山 直子, 坂東 弘教, 船曳 あゆみ, 冨永 洋一

  (一社)日本糖尿病学会, 2012年04月, 糖尿病, 55(Suppl.1) (Suppl.1), S - 170, 日本語


• ステロイド補充にて下肢拘縮が軽快したACTH単独欠損症の一例

  坂東 弘教, 陳 慶祥, 田中 雄志, 船曳 あゆみ, 冨永 洋一

  (一社)日本内分泌学会, 2011年12月, 日本内分泌学会雑誌, 87(3) (3), 954 - 954, 日本語


• 糖尿病の新しい血糖降下薬の臨床 インクレチン製剤の臨床の基礎

  芳野 弘, 播 悠介, 藤永 潤, 坂東 弘教, 片山 茂明, 橋口 由香里, 上浦 望, 村田 成正, 野中 英美, 福永 馨, 八木 規夫, 坂井 誠, 谷 聡, 松岡 彰, 老籾 宗忠

  (一財)甲南病院, 2011年04月, 甲南病院医学雑誌, 28, 5 - 7, 日本語

  記事・総説・解説・論説等（国際会議プロシーディングズ）


• 誤嚥性肺炎発症時のHbA1c・血糖・栄養状態における予後の検討

  坂東 弘教, 片山 茂明, 橋口 由香里, 上浦 望, 芳野 弘, 福永 馨, 八木 規夫, 坂井 誠, 老籾 宗忠

  (一社)日本糖尿病学会, 2011年04月, 糖尿病, 54(Suppl.1) (Suppl.1), S - 112, 日本語


• 糖尿病ではAtherogenic phenotypeは高齢でも残存する

  芳野 弘, 坂東 弘教, 片山 茂明, 橋口 由香里, 上浦 望, 福永 馨, 八木 規夫, 坂井 誠, 老籾 宗忠, 松本 知子, 中野 三郎, 芳野 原, 長谷川 和男

  (一社)日本糖尿病学会, 2011年04月, 糖尿病, 54(Suppl.1) (Suppl.1), S - 153, 日本語


• 腸腰筋膿瘍を認めた肝硬変合併2型糖尿病の一例

  片山 茂明, 坂東 弘教, 橋口 由香里, 芳野 弘, 福永 馨, 八木 規夫, 坂井 誠, 老籾 宗忠

  (一社)日本糖尿病学会, 2011年03月, 糖尿病, 54(3) (3), 215 - 215, 日本語


• Fanconi症候群、腎尿細管性アシドーシス、ビタミンD欠乏、原発性胆汁性肝硬変合併により著明に重症化した低リン血症性骨軟化症の一例

  井上 喜文, 坂東 弘教, 橋本 尚子, 中村 友昭, 村脇 あゆみ, 西海 智子, 比佐 伊都子, 廣田 勇士, 坂口 一彦, 高橋 裕, 清野 進, 今西 康雄, 梶 博史

  (一社)日本内分泌学会, 2009年04月, 日本内分泌学会雑誌, 85(1) (1), 363 - 363, 日本語

• 先駆的解析法に基づく先天性下垂体機能低下症の病因解明と新規疾患概念の創出

  坂東 弘教

  日本学術振興会, 科学研究費助成事業 国際共同研究加速基金(国際共同研究強化(B)), 国際共同研究加速基金(国際共同研究強化(B)), 神戸大学, 2021年10月 - 2026年03月, 研究代表者

  本研究は先天性下垂体機能低下症の原因・病態について、申請者の持ちうるマテリアルを米国ミシガン大学のSally Camper研究室の持つ先進的な手法を用いて解析を行うものである。 [母体内環境因子曝露による下垂体機能低下症] （研究予定ではCdon遺伝子欠損マウスの予定であったが、入手困難であり、Otx2遺伝子欠損マウスに変更した)本研究課題の共同研究者である、大阪母子医療センター部長 松尾勲先生よりOtx2ヘテロの凍結胚(ICR background)を分与頂き、マウスの維持を開始した。既報通り、ICR backgroundでは表現型も正常であった。下垂体はLH, FSHを分泌することで性周期の維持にも働くことが知られているが、生殖も問題なく行っていることから、下垂体の各種ホルモン分泌異常が無いことも推察される結果であった。これまでの報告では、同マウスにおいての下垂体ホルモンの分泌状態については推察がなされていなかったが、妊孕性を評価することで同マウスが通常状態では明らかな異常がないことを推察し得る結果を得ることが出来た。現在当初の目標である母体内での環境因子曝露を開始しているところであり、次年度早々には下垂体を含めた頭部の形成異常について評価し得るものと思われる。 [日本人サンプルを用いた、新規先天性下垂体機能低下症の原因遺伝子の同定] 現在申請者の所属する神戸大学医学部の他、複数の共同研究者から先天性下垂体機能低下症の患者サンプルを収集中である。本年夏ころまでには収集し終え、解析に移る予定である、


• 母体内環境因子による下垂体形成異常の解明

  坂東 弘教

  日本学術振興会, 科学研究費助成事業 若手研究, 若手研究, 神戸大学, 2021年04月 - 2024年03月, 研究代表者

  先天性下垂体機能低下症(CPHD)は30超の原因遺伝子が報告されているのにも関わらず、症例の大半は原因遺伝子などが不明である。また、原因遺伝子が明らかになった家族例であっても下垂体を含めた頭部を中心とした症候が多彩であることが特徴であるため、診断に難渋することが多い。原因の一つとして知られている全前脳胞症のモデルを発展させることを目標にした。特に本研究課題ではCPHD発症の機序の可能性として、遺伝子変異に伴って発症閾値が低下している状態に加え、母体内環境因子への曝露に伴うエピジェネティック異常などの原因によって発症する可能性につき検討した。本検討では通常状態では正常の表現型を呈するOtx2遺伝子のヘテロ接合性欠損マウスを用い、母体内にアルコールを腹腔内投与を行うことで検討を行った。共同研究者から得られたOtx2欠損マウスの飼育を開始し、今後の更なる解析の準備を整えることが出来た。 また、申請者がこれまでに行ってきた下垂体形成モデルから得られた分子について、下垂体ラトケ嚢胞の病理診断マーカーとして用いうる可能性について明らかにすることを目標に、共同研究者から得たヒトサンプルを用いた免疫染色を進め、各種マーカーが使用できることを明らかにした。 また、研究者がこれまで行ってきた新たな疾患概念、”傍腫瘍自己免疫性下垂体炎”に関して研究を進め、国際誌に総説を投稿するとともに、新たな症例について検討を平行して行った。 （なお、国際共同研究強化Bの採択に伴い、本研究課題については中止となった）


• 自己免疫性内分泌機能低下症の病態解明

  坂東 弘教

  日本学術振興会, 科学研究費助成事業 若手研究(B), 若手研究(B), 神戸大学, 2017年04月 - 2019年03月, 研究代表者

  本研究は下垂体を中心とした自己免疫性内分泌疾患の発症メカニズムの解明と臨床応用を目指し、新規症例の解析から診断・治療への臨床応用の基盤確立が目的である。腫瘍に合併し下垂体機能低下症を起こした症例を解析し、腫瘍随伴症候群っとしての新たな下垂体機能低下症の提唱を行った。また、下垂体に特異的に存在する転写因子"PIT-1"に対する自己抗体を有する症候群（抗PIT-1抗体症候群)についてPIT-1陽性細胞の解析を行い、PIT-1抗原がMHC classIと共に細胞表面に提示されていることを示した。また、IgG4関連疾患の代表である自己免疫性膵炎における下垂体炎の頻度について臨床研究を行った。